Healthpeak Properties (DOC) 10-K risk factor changes: FY2024 vs FY2023
The 2024-12-31 10-K against the 2023-12-31 one, compared heading by heading and sentence by sentence.
Item 1A81 rewritten47 added110 removed453 unchanged
All filing items1,664 rewritten1,045 added712 removed1,991 unchanged
Summary
counted, not written
- Item 1A lists 56 risk factor headings: 3 new, 7 reworded and 46 unchanged since FY2023. 13 headings from FY2023 no longer appear.
- Sentence by sentence, 1,045 added, 712 removed, 1,664 rewritten and 1,991 unchanged across 19 items that differ.
New Item 1A headings (3)
- We may be negatively impacted by macroeconomic trends that may increase construction, labor, and other operating costs for us and our tenants, operators, and borrowers.
- The use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors presents risks and challenges that may adversely impact our business and operating results or the business and operating results of our tenants and vendors or may adversely impact the requirements and demand for properties.AI
- Changes in federal, state, or local laws or regulations may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate.
Removed Item 1A headings (13)
- We may be negatively impacted by macroeconomic trends, including rising inflation and interest rates, increased construction and labor costs, and historically low unemployment.
- An adverse outcome in any litigation or other legal proceedings relating to the Merger Agreement, or the transactions contemplated thereby, could have a material adverse impact on our business and our ability to consummate the transactions contemplated by the Merger Agreement.
- The Exchange Ratio is fixed and will not be adjusted in the event of any change in the stock or share prices, respectively, of either us or Physicians Realty Trust.
- Our stockholders will be significantly diluted by the Mergers.
- The Combined Company expects to incur substantial expenses related to the Mergers.
- Following the Mergers and the transactions contemplated by the Merger Agreement, the Combined Company may be unable to retain key employees.
- The Mergers will result in changes to the board of directors of the Combined Company that may affect the strategy of the Combined Company as compared to that of the Company and Physicians Realty Trust individually.
- The future results of the Combined Company will suffer if the Combined Company does not effectively manage its operations following the Mergers and the transactions contemplated by the Merger Agreement.
- The trading price of shares of the Combined Company common stock following the Mergers may be affected by factors different from those affecting the price of shares of our common stock before the Mergers.
- Counterparties to certain significant agreements with Physicians Realty Trust may exercise contractual rights under such agreements in connection with the Mergers, including in certain cases the right to acquire properties owned by Physicians Realty Trust.
- The Combined Company’s anticipated level of indebtedness will increase upon completion of the Mergers and may increase the related risks Healthpeak currently faces.
- We may incur adverse tax consequences if Physicians Realty Trust has failed to qualify as a REIT for U.S. federal income tax purposes.
- The market price of shares of the Combined Company common stock may decline as a result of the Mergers and the transactions contemplated by the Merger Agreement.
Reworded Item 1A headings (7)
- We may be negatively impacted by the insolvency or bankruptcy
[removed: of][added: of, or the inability to obtain funding by,] one or more of our major tenants, operators, or borrowers. - Uninsured or underinsured losses could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated
[removed: expense.][added: expenses.] - We may be unable to successfully
[removed: foreclose or]exercise rights on the collateral securing our real estate-related loans and, even if we are successful in[removed: our foreclosure or realization efforts,][added: exercising those rights,] we may be unable to successfully operate, occupy, or reposition the underlying real estate. - We may not be able to successfully integrate or operate
[removed: acquisitions,][added: acquisitions and/or internalize property management,] or may incur unanticipated liabilities. [removed: ESG][added: Corporate impact] and sustainability commitments and requirements, as well as stakeholder expectations, may impose additional costs and expose us to new risks.- We could be negatively impacted by legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid
[removed: Services.][added: Services or other legislative or regulatory changes affecting REITs or the industries in which we operate.] [removed: Following the Mergers, the Combined Company][added: We] may be unable to [added: fully] integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies [added: of the Merger] and[removed: other]benefits of[removed: the Mergers][added: property management internalization] or do so within the anticipated time frame.
A heading is new when no FY2023 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
24 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2024; struck-through words were in FY2023. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. Risk Factors
81 rewritten, 47 added, 110 removed, 453 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
- risks related to tax, including REIT-related risks, and related to our jurisdiction of incorporation and our structure as an [removed: UPREIT;][added: UPREIT.]
[removed: Many] [added: In recent periods, many] of our costs, including labor costs, construction costs, utilities, and other operating and administrative costs, have [removed: been, and may continue to be,] [added: been adversely] affected by [removed: inflation and] [added: macroeconomic trends, including inflation,] price [removed: volatility.][added: volatility, declines in economic growth rates, and changes in unemployment.]
These macroeconomic trends have [removed: been, and may continue to be,] [added: been] exacerbated by [removed: responses to the Covid pandemic,] [added: higher interest rates,] supply chain disruptions, [removed: the conflicts between Russia and Ukraine and in the Middle East,] [added: geopolitical conflicts,] federal government deficits, [added: responses to the Covid pandemic,] and other international and domestic events impacting the macroeconomic environment.
[removed: In addition, interest] [added: Interest] rates [removed: rose substantially in 2022 and 2023 and] may continue to [removed: rise and] remain elevated [added: above historical levels] for the foreseeable [removed: future.][added: future or rise again.]
U.S. government policies implemented to address inflation, including actions by the Federal Reserve System’s Federal Open Market Committee (the “FOMC”) to increase short-term interest rates, [removed: have led to] [added: resulted in] increases in interest rates in the credit markets and other impacts on the macroeconomic environment.
The FOMC may [removed: continue to raise the federal funds rate or] maintain a higher federal funds rate for a longer period of time, [added: or may determine to raise the federal funds rate again,] either of which would likely lead to higher short-term interest rates and the possibility of lower asset values, slowing economic growth and increasing the possibility of a recession.
[removed: Increased] [added: Historically higher] interest rates have caused, and may [removed: continue to] [added: in the future] cause, unfavorable financing terms and increased interest costs for variable rate debt and new debt.
Further, actions by the [removed: FMOC] [added: FOMC] to decrease short-term interest rates could lead to inflationary pressures.
We may not be able to offset additional costs caused by inflation, [removed: increased] [added: higher] interest rates, or other macroeconomic trends by passing them through, or increasing the rates we charge, to tenants and residents.
Furthermore, rising labor costs and personnel shortages [removed: have increased, and] may [removed: continue to increase, the cost of our,] [added: adversely impact us] or our [removed: tenants’, operators’,] [added: tenants, operators,] and [removed: borrowers’, workforce.][added: borrowers.]
Competitive [removed: pressures, including historically low unemployment,] [added: pressures] may require that we or our tenants, operators, or borrowers enhance pay and benefits packages to compete effectively for such personnel.
Additionally, changing [removed: technologies] [added: technologies, political] and [added: regulatory conditions, and] cultural trends could negatively impact future demand for our properties, which could have a material adverse effect on our business, results of operations, and financial condition.
Life [removed: science industry] [added: science industry] changes could have a material adverse effect on our business, results of operations, and financial condition.
If economic, financial, regulatory, or industry conditions [removed: continue to] adversely affect the life science industry, we may be unable to lease or re-lease our lab properties in a timely manner or at profitable rates or with favorable terms.
- [added: new and emerging laws aimed at the life science/biotechnology industry, increasing regulatory requirements and compliance costs, as well as] healthcare reforms and reimbursement policies of government or private healthcare payors, including [removed: pricing] [added: price] controls for prescription drug prices;
- economic conditions [added: potentially] restricting growth opportunities.
We may be negatively impacted by the insolvency or bankruptcy [removed: of] [added: of, or the inability to obtain funding by,] one or more of our major tenants, operators, or borrowers.
A downturn or slowdown in this sector would have a greater adverse impact on our business than if we had investments across multiple sectors, and could negatively impact the ability of our tenants, operators, and borrowers to meet their obligations to us, as well as [removed: the] [added: their] ability to maintain historical rental and occupancy rates, which could have a material adverse effect on our business, results of operations, and financial condition.
In addition, infrastructure improvements for [added: outpatient medical and] lab properties typically are significantly more expensive than improvements to other property types due to the highly specialized nature of the [removed: properties] [added: properties,] and [added: with respect to lab properties,] the greater lease square footage often required by lab tenants.
- legal and regulatory hurdles, including moratoriums on development and redevelopment [removed: activities;][added: activities, net zero or carbon neutrality requirements, or other building and energy performance requirements;]
- [removed: increased] [added: higher] interest rates;
If a hospital whose campus is located near one of our outpatient medical buildings is unable to meet its financial obligations, and if an affiliated healthcare system is unable to support that hospital or goes bankrupt, the hospital may be unable to successfully compete or could be forced to [removed: close or] [added: close,] relocate, [added: or be sold to another provider,] which could adversely impact its ability to attract physicians and other healthcare-related users.
Accordingly, our operators of these properties depend on attracting seniors with appropriate levels of income and assets, which may be affected by many factors, including: (i) prevailing economic and market trends, including general inflationary pressures; (ii) consumer confidence; (iii) demographics; (iv) property condition and safety; (v) public perception about such properties; [removed: and] (vi) social and environmental [removed: factors.][added: factors; and (vii) changes in consumer preferences (such as favoring home health services instead of residing in a senior housing community).]
We are subject to increased exposure to adverse conditions affecting the geographies in which our properties are located, including: (i) downturns in local economies [removed: and] [added: or] increases in unemployment rates; (ii) changes in local real estate conditions, including increases in real estate taxes and property insurance premiums; (iii) increased competition; (iv) decreased demand; (v) changes in [removed: state] [added: political administrations, or federal, state,] and local legislation, including changes affecting business or property taxes; (vi) local climate events and natural disasters and other catastrophic events, such as pandemics, earthquakes, hurricanes, windstorms, flooding, wildfires, and mudslides and other physical climate risks, including water stress and heat stress; and (vii) failures of regional banks.
Intensifying natural disasters [removed: including] [added: resulting from] climate change and extreme weather events, coupled with [removed: the current economic climate] [added: macroeconomic factors,] have directly affected the availability of insurance, premiums, deductibles, and capacity that insurers are willing to underwrite.
Uninsured or underinsured losses could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated [removed: expense.][added: expenses.]
In particular, (i) a significant portion of our lab development projects and approximately 67% of our lab portfolio (based on gross asset value as of December 31, [removed: 2023)] [added: 2024)] was concentrated in California, which is known to be subject to earthquakes, wildfires, and other natural disasters, and (ii) approximately [removed: 69%] [added: 68%] of our CCRC portfolio (based on gross asset value as of December 31, [removed: 2023)] [added: 2024)] was concentrated in Florida, which is known to be subject to hurricanes.
We may be unable to successfully [removed: foreclose or] exercise rights on the collateral securing our real estate-related loans and, even if we are successful in [removed: our foreclosure or realization efforts,] [added: exercising those rights,] we may be unable to successfully operate, occupy, or reposition the underlying real estate.
If a borrower defaults under one of our [removed: mortgages,] [added: real estate related loans,] we may look to [removed: foreclose on] [added: exercise our rights under] the [removed: loan or take additional actions,] [added: loan,] including acquiring title to the collateral via [added: deed in lieu of foreclosure, foreclosure,] statutory or judicial [removed: foreclosure] [added: foreclosure,] or commencing collection litigation.
We may [added: also] determine that substantial improvements or repairs to the property are necessary in order to maximize the property’s investment potential.
Borrowers [added: and guarantors] may contest enforcement of foreclosure or other remedies, seek bankruptcy protection against our exercise of enforcement or other remedies, and/or bring claims for lender liability in response to actions to enforce [removed: mortgage] [added: borrower] obligations.
[removed: Foreclosure] [added: Enforcement] or collections-related costs, high loan-to-value ratios, healthcare regulatory issues or consents, or declines in the value of the property, may prevent us from realizing an amount equal to our [removed: mortgage] [added: loan] balance upon [removed: foreclosure] [added: enforcement] or conclusion of litigation, and we may be required to record a valuation allowance for such losses.
Even if we are able to successfully [removed: foreclose] [added: exercise our rights] on the collateral securing our real estate-related loans, we may acquire properties for which we may be unable to expeditiously secure tenants or operators, if at all, or that are burdened with healthcare regulatory compliance issues that need to be addressed, or we may acquire equity interests that we are unable to immediately resell or otherwise liquidate due to limitations under the securities laws, either of which would adversely affect our ability to fully recover our investment.
For additional information on risks related to [removed: the consummation of] [added: integration following] the [removed: Mergers,] [added: Merger,] see “—Risks Relating to [removed: the Mergers”] [added: Integration following our Merger with Physicians Realty Trust”] below.
We may not be able to successfully integrate or operate [removed: acquisitions,] [added: acquisitions and/or internalize property management,] or may incur unanticipated liabilities.
Successful integration of acquired companies [added: and/or internalization of the property management function, as applicable,] depends primarily on our ability to consolidate operations, systems, procedures, properties, and personnel, and to eliminate redundancies and reduce costs.
We may encounter difficulties in these [removed: integrations.][added: integrations and property management internalizations.]
Potential difficulties associated with acquisitions [added: and property management internalizations] include: (i) our ability to effectively monitor and manage our expanded portfolio of properties; (ii) the loss of key employees; (iii) the disruption of our ongoing business or that of the acquired entity; (iv) possible inconsistencies in standards, controls, procedures, and policies; and (v) the assumption of unexpected liabilities and claims, including:
- liabilities, claims, and litigation, whether or not incurred in the ordinary course of business, relating to periods prior to [removed: our] [added: the] acquisition;
- liabilities for taxes relating to periods prior to [removed: our] [added: the] acquisition.
- risks relating to integration and property management internalization following our Merger with Physicians Realty Trust;
We may be negatively impacted by macroeconomic trends that may increase construction, labor, and other operating costs for us and our tenants, operators, and borrowers.
If any of these adverse macroeconomic trends continue or recur in the future, our business and results of operations may be negatively impacted.
Interest rates rose substantially in 2022 and 2023.
There have been, and there are expected to continue to be, advances and changes in technology, payment models, healthcare delivery models, regulation, and consumer behavior, preferences, and perception that could reduce demand for on-site activities provided at our properties.
If our tenants, operators, or borrowers are unable to adapt to long-term changes in demand, their financial condition could be materially impacted and our business, financial condition, and results of operations could be adversely affected.
In addition, hospitals can also be adversely affected by increasing legal and regulatory scrutiny and hurdles, including requirements for hospitals to be able to engage in certain transactions or change owners or operators, which could impact the financial viability of the hospitals.
At the same time, diverging views on corporate impact may emerge from regulators and stakeholders, potentially resulting in increased scrutiny of our corporate impact practices and political or reputational risk.
In addition, metrics and quantitative data we disclose related to our corporate impact and sustainability commitments are based on and verified in accordance with standards that are different from U.S. generally accepted accounting principles.
Such data and metrics may be subject to measurement uncertainties resulting from limitations inherent in the nature and the methods used for determining such data.
The selection of different but acceptable measurement techniques can result in materially different measurements.
Our third-party service providers may also experience unexpected power losses, computer system failures, or data network disruptions, negatively impacting the systems or solutions we depend on.
If our third-party providers face a security incident or other interruptions, or if there is a flaw or failed software update in the third-party software used in our systems, our information systems may become disabled or inaccessible.
This could limit access to our data and business information, potentially causing significant disruptions to our operations.
The use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors presents risks and challenges that may adversely impact our business and operating results or the business and operating results of our tenants and vendors or may adversely impact the requirements and demand for properties.
We may use generative artificial intelligence and/or machine learning (collectively, “AI”) tools in our operations.
If our peers use AI tools to optimize operations and we fail to utilize AI tools in a comparable manner, we may be competitively disadvantaged.
However, while AI tools may facilitate optimization and operational efficiencies, they also have the potential for inaccuracy, bias, infringement or misappropriation of intellectual property, and risks related to data privacy and cybersecurity.
The use of AI tools may introduce errors or inadequacies that are not easily detectable, including deficiencies, inaccuracies, or biases in the data used for AI training, or in the content, analyses, or recommendations generated by AI applications.
The results of such errors or inadequacies may adversely affect our business, financial condition, and results of operations.
The legal requirements relating to AI continue to evolve and remain uncertain, including how legal developments could impact our business and ability to enforce our proprietary rights or protect against infringement of those rights.
Cybersecurity threat actors may utilize AI tools to automate and enhance cybersecurity attacks against us.
We utilize software and platforms designed to detect such cybersecurity threats, including AI-based tools, but these threats could become more sophisticated and harder to detect and counteract, which may pose significant risks to our data security and systems.
Such cybersecurity attacks, if successful, could lead to data breaches, loss of confidential or sensitive information, and financial or reputational harm.
The integration of AI tools in the healthcare industry may present significant opportunities and risks, including for our tenants.
For example, in the life science industry, AI predictive models have the potential to be utilized broadly across various stages of drug development.
Physicians in our outpatient medical portfolio may use AI tools to run comprehensive diagnostic tests.
However, the adoption of AI tools also introduces a complex risk landscape for our tenants, similar to those risks described above.
Moreover, the adoption of AI tools by our tenants may lead to infrastructure requirements that our buildings currently do not accommodate, such as increased power needs for high-performance computing.
Infrastructure upgrades may require significant capital expenditures and could potentially impact the environmental footprint of our building operations.
Our vendors may use AI tools in their products or services without our knowledge, and the providers of these tools may not meet the evolving regulatory or industry standards for privacy and data protection.
Consequently, this may inhibit our or our vendors’ ability to uphold an appropriate level of service and data privacy.
If we, our vendors, or other third parties with which we conduct business experience an actual or perceived breach of privacy or security incident due to the use of AI, we may be adversely impacted, lose valuable intellectual property or confidential information, and incur harm to our reputation and the public perception of the effectiveness of our security measures.
In addition, investors, analysts, and other market participants may use AI tools to process, summarize or interpret our financial information or other data about us.
The use of AI tools in financial and market analysis may introduce risks similar to those described above, including an inaccurate interpretation of our financial or operational performance or market trends or conditions, which in turn could result in inaccurate conclusions or investment recommendations.
Federal and state authorities have become increasingly focused on the review and potential regulation of healthcare transactions for impacts on costs, access to care, and quality, which could involve lengthy review and approval periods, enhanced disclosure obligations, impact analysis, public notices, and hearings.
Such regulation could adversely impact the time and cost of completing transactions and, in certain circumstances, affect the feasibility of pursuing or completing such transactions.
- minimum staffing levels and other staffing and quality requirements;
- pre- and post-payment reviews and audits by governmental authorities, which could result in recoupments, denials or delay of payments;
In addition, changes in federal, state, or local laws affecting the healthcare or life sciences industries, particularly that apply to REITs, or changes in the scope, interpretation, or enforcement of the related regulatory frameworks could adversely affect us or our tenants, operators, or borrowers.
- risks relating to the Mergers;
- risks relating to the Combined Company following the Mergers;
- risks relating to the status of Physicians Realty Trust as a REIT; and
- risks relating to an investment in the Combined Company’s common stock following the Mergers and the transactions contemplated by the Merger Agreement.
We may be negatively impacted by macroeconomic trends, including rising inflation and interest rates, increased construction and labor costs, and historically low unemployment.
HHS interpretation of applicable terms and requirements has evolved over time, and may continue to evolve.
The interpretation and implementation of PRF requirements and related guidance remains uncertain, and there can be no assurance that we or our operators are or will remain in compliance with all PRF and Covid relief program requirements and interpretative guidance.
PRF guidance or interpretations could change in ways that adversely impact the PRF funding we or our operators received, recognized, or are able to retain.
Risks Relating to the Mergers
An adverse outcome in any litigation or other legal proceedings relating to the Merger Agreement, or the transactions contemplated thereby, could have a material adverse impact on our business and our ability to consummate the transactions contemplated by the Merger Agreement.
On October 29, 2023, the Company and Physicians Realty Trust entered into the Merger Agreement with DOC DR Holdco, LLC (formerly known as Alpine Sub, LLC), a Maryland limited liability company and a wholly owned subsidiary of the Company (“DOC DR Holdco”), DOC DR, LLC (formerly known as Alpine OP Sub, LLC), a Maryland limited liability company and a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”), and Physicians Realty L.P. (the “Physicians Partnership”).
The Merger Agreement provides for (a) the merger of Physicians Realty Trust with and into DOC DR Holdco (the “Company Merger”), with DOC DR Holdco surviving as a wholly owned subsidiary of the Company (the “Company Surviving Entity”); (b) immediately following the effectiveness of the Company Merger, the contribution by the Company to Healthpeak OP, a Maryland limited liability company, of all of the outstanding equity interests in the Company Surviving Entity (the “Contribution”); and (c) immediately following the Contribution, the merger of the Physicians Partnership with and into DOC DR OP Sub (the “Partnership Merger”), with DOC DR OP Sub surviving as a wholly owned subsidiary of Healthpeak OP (the “Partnership Surviving Entity”).
Transactions like the Mergers are frequently the subject of litigation or other legal proceedings, including actions alleging that either our Board of Directors or Physicians Realty Trust’s board of trustees, as applicable, breached its respective duties to its stockholders or shareholders, respectively, or other equity holders by entering into the Merger Agreement; by failing to obtain a greater value in the transaction for the Company’s stockholders or Physicians Realty Trust’s shareholders or other equity holders; by failing to make adequate disclosures; or by otherwise failing to fulfill their fiduciary duties or statutory obligations.
As discussed in Note 11 to the Consolidated Financial Statements, three purported stockholders of the Company and four purported shareholders of Physicians Realty Trust have filed (and additional shareholders or stockholders, as applicable, of Physicians Realty Trust and/or the Company may file) complaints relating to the Mergers, and Physicians Realty Trust has received correspondence from multiple purported shareholders of Physicians Realty Trust relating to the Mergers.
With respect to such litigation, and if additional litigation or other legal proceedings are brought against us or against our Board of Directors in connection with the Merger Agreement, or the transactions contemplated thereby, we will defend against it, but we might not be successful in doing so.
An adverse outcome in such matters, as well as the costs, time, and effort of a defense, even if successful, could have a material adverse effect on our ability to consummate the Mergers or on our business, results of operations, or financial position, including through the delay of the Mergers with consequent direct and indirect costs, the possible diversion of either company’s resources, or the distraction of key personnel.
The Exchange Ratio is fixed and will not be adjusted in the event of any change in the stock or share prices, respectively, of either us or Physicians Realty Trust.
As a result of the Mergers, and through a series of transactions, (i) each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares to be canceled in accordance with the Merger Agreement) will be converted into the right to receive 0.674 shares of Company common stock (the “Merger Consideration”), without interest, plus cash in lieu of consideration for fractional shares, but subject to any withholding required under applicable tax laws, and (ii) each Partnership OP Unit (as defined in the Merger Agreement) will be converted into common units in the Partnership Surviving Entity equal to the 0.674 Exchange Ratio.
The Exchange Ratio will not be adjusted for changes in the market prices of either shares of our common stock or Physicians Realty Trust’s common shares.
Changes in the market price of Physicians Realty Trust common shares prior to the effective time of the Mergers will affect the market value of the Merger Consideration that Physicians Realty Trust shareholders will receive on the closing date of the Mergers.
Share price changes may result from a variety of factors (many of which are beyond our or Physicians Realty Trust’s control), including the following factors:
- market reaction to the prospects of Healthpeak and its subsidiaries after the Company Merger (the “Combined Company”);
- changes in the respective businesses, operations, assets, liabilities, and prospects of the Company and Physicians Realty Trust;
- changes in market assessments of the business, operations, financial position, and prospects of any of the Company, Physicians Realty Trust, or the Combined Company;
- market assessments of the likelihood that the Mergers will be completed;
- interest rates, general market and economic conditions, and other factors generally affecting the market prices of our common stock and Physicians Realty Trust’s common shares;
- federal, state and local legislation, governmental regulation, and legal developments in the businesses in which we and Physicians Realty Trust operate; and
- other factors beyond the control of the Company and Physicians Realty Trust, including those described or referred to in this “Risk Factors” section.
The market price of Company common stock at the closing of the Mergers may vary from its price on the date the Merger Agreement was executed, on the date of the joint proxy statement/prospectus, and on the date of our special meeting.
As a result, the market value of the Merger Consideration represented by the Exchange Ratio will also vary.
If the market price of shares of Company common stock increases between the date the Merger Agreement was signed or the date of the special meeting and the closing of the Mergers, Physicians Realty Trust’s shareholders will receive shares of Company common stock that have a market value upon completion of the Company Merger that is greater than the market value of such shares calculated pursuant to the Exchange Ratio on the date the Merger Agreement was signed or on the date of the special meeting, respectively.
Alternatively, if the market price of shares of Company common stock declines between the date the Merger Agreement was signed or the date of the special meeting and the closing of the Mergers, including for any of the reasons described above, Physicians Realty Trust’s shareholders will receive shares of Company common stock that have a market value upon completion of the Company Merger that is less than the market value of such shares calculated pursuant to the Exchange Ratio on the date the Merger Agreement was signed or on the date of the special meeting, respectively.
Our stockholders will be significantly diluted by the Mergers.
The Mergers will significantly dilute the ownership position of our stockholders.
Upon completion of the Mergers, based on the number of shares of Company common stock and Physicians Realty Trust common shares outstanding as of December 31, 2023, it is estimated that legacy Company common stockholders will own approximately 77% of the common stock of the Combined Company, and legacy Physicians Realty Trust common shareholders will own approximately 23% of the common stock of the Combined Company.
Additionally, because the Company will be issuing shares of Company common stock to certain holders of Partnership OP Unit in the Partnership Merger, each outstanding share of Company common stock after the completion of the Mergers will represent a smaller percentage of the voting power of the Company than if such shares of common stock had not been issued in the Partnership Merger.
The Company may also issue additional shares of common stock or preferred stock in the future, which would create further dilution.
Consequently, our stockholders, as a general matter, will have less influence over the management and policies of the Combined Company after the effective time of the Mergers than they currently exercise over the management and policies of the Company.
Risks Relating to the Combined Company Following the Mergers
The Combined Company expects to incur substantial expenses related to the Mergers.
An excerpt. Shown here: 40 of 81 rewritten, 40 of 47 added and 40 of 110 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2024 filing and the FY2023 filing.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
258 rewritten, 127 added, 123 removed, 193 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
This section generally discusses the results of our operations for the year ended December 31, [removed: 2023] [added: 2024] compared to the year ended December 31, [removed: 2022.][added: 2023.]
For a discussion of the year ended December 31, [removed: 2022] [added: 2023] compared to the year ended December 31, [removed: 2021,] [added: 2022,] please refer to Part II, Item 7.
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, [removed: 2022] [added: 2023] filed with the SEC on February [removed: 8, 2023.][added: 9, 2024.]
[removed: Rising] [added: Increased] interest rates, [removed: high inflation, supply chain disruptions,] ongoing geopolitical tensions, and [removed: increased] volatility in public and private equity and fixed income markets have led to increased costs and [removed: limited] [added: limitations on] the availability of capital.
In addition, increased interest rates have [removed: negatively affected] [added: and could continue to adversely impact] our borrowing costs, the fair value of our fixed rate [removed: instruments.][added: instruments, transaction volume, and real estate values generally, including our real estate.]
[removed: Our] [added: To the extent our] tenants [removed: and] [added: and/or] operators have also experienced increased costs, liquidity constraints, and financing difficulties due to the foregoing macroeconomic and market conditions, [removed: which could cause them to] [added: they may] be unable or unwilling to make payments or perform their obligations when due.
We have also been affected by [removed: significant inflation in construction] [added: increased] costs [removed: over the past few years,] [added: relating to tenant improvements and construction,] which, together with [removed: rising] [added: higher] costs of capital, have [removed: negatively affected] [added: adversely affected, and in] the [added: future may adversely affect, the] expected yields on our development and redevelopment projects.
We continuously monitor the effects of domestic and global [removed: events, including but not limited to inflation, labor shortages, supply chain matters, rising interest rates, and challenges in the financial markets,] [added: events] on our operations and financial position, [removed: as well as] [added: and] on the operations and financial position of our tenants, operators, and borrowers, to [removed: ensure that we] [added: enable us to] remain responsive and adaptable to the dynamic changes in our operating environment.
[removed: On October 29, 2023, we entered into a] [added: Pursuant to the terms set forth in the] Merger [removed: Agreement with Physicians Realty Trust,] [added: Agreement, on] the [removed: Physicians Partnership, and certain of our subsidiaries, pursuant to which, among other things, and through a series of transactions (the “Mergers”), (i)] [added: Closing Date,] each outstanding [removed: common] share of Physicians Realty Trust (other than Physicians Realty Trust common shares [removed: to be] [added: that were] canceled in accordance with the Merger Agreement) [removed: will be] [added: automatically] converted into the right to receive 0.674 [removed: (the “Exchange Ratio”)] shares of our common [removed: stock, and (ii) each outstanding common unit of the Physicians Partnership will be converted into common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.][added: stock.]
- In January 2024, we sold a 65% interest in two lab buildings in San Diego, California [added: (the “Callan Ridge JV”)] to a third-party for net proceeds of $128 million.
- During the year ended December 31, [removed: 2023,] [added: 2024,] the following projects were placed in service: (i) [removed: portions] [added: a portion] of two lab development projects with [removed: aggregate] [added: total project] costs of [removed: $233] [added: $83] million, (ii) [removed: one lab] [added: two outpatient medical] development [removed: project] [added: projects] with total [added: project] costs of [removed: $171] [added: $62] million, (iii) [removed: a portion of] one [removed: lab redevelopment project with total costs of $43 million, (iv) four] outpatient medical [removed: redevelopment projects with aggregate costs of $42 million, (v) a portion of one lab redevelopment building] [added: development project] held in [removed: one of our unconsolidated South San Francisco JVs] [added: a consolidated joint venture] of which our share of total project costs was [removed: $32] [added: $22] million, [removed: (vi)] [added: (iv)] one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was $15 million, [removed: (vii)] [added: (v)] one lab redevelopment project with total [added: project] costs of $14 million, [removed: and (viii)] [added: (vi) a portion of] one [removed: CCRC] [added: lab] redevelopment project with total [added: project] costs of [removed: $7] [added: $13 million, and (vii) a portion of one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was $9] million.
- [removed: We have secured commitments for] [added: In March 2024, we executed] a $750 million [removed: five-year] [added: five year] unsecured term loan (the [removed: “2024] [added: “2029] Term [removed: Loan”), to be incurred] [added: Loan”)] as an incremental facility under [removed: our existing] [added: the] term loan agreement.
In January 2024, we entered into forward-starting interest rate swap instruments that are designated as cash flow hedges that [removed: will] effectively [removed: establish] [added: established] a fixed interest rate for the [removed: 2024] [added: 2029] Term Loan at a blended [removed: contractual] [added: effective interest] rate of [removed: 4.5%.][added: 4.66%.]
Quarterly [added: common stock] cash dividends paid during [removed: 2023] [added: 2024] aggregated to $1.20 per share.
[removed: On January 31, 2024,] [added: In February 2025,] our Board of Directors declared [removed: a] [added: an increase in the] quarterly [added: common stock] cash [removed: dividend of] [added: dividend, from] $0.30 [added: to $0.305] per [removed: common] share.
The dividend will be paid on February 26, [removed: 2024] [added: 2025] to stockholders of record as of the close of business on February 14, [removed: 2024.][added: 2025.]
We evaluate our business and allocate resources among our [removed: reportable business] [added: operating] segments: (i) [removed: lab, (ii)] outpatient medical, [removed: and] [added: (ii) lab,] (iii) [removed: CCRC.][added: CCRC, (iv) an interest in our unconsolidated SWF SH JV, and (v) loans receivable.]
Under the [removed: lab and] outpatient medical [added: and lab] segments, we [removed: invest through the acquisition, development,] [added: own, operate,] and [removed: management of lab buildings,] [added: develop] outpatient medical buildings, [added: hospitals,] and [removed: hospitals.][added: lab buildings.]
[removed: These] [added: The SWF SH JV and loans receivable are] non-reportable segments [added: that] have been presented on [removed: an aggregate] [added: a combined] basis herein.
[removed: NOI and] Adjusted NOI [removed: are] [added: is a] non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial [removed: measures] [added: measure] used to evaluate the operating performance of real estate.
[added: Adjusted] NOI [removed: is defined as] [added: represents] real estate revenues (inclusive of rental and related revenues, resident fees and services, [removed: income from direct financing leases,] and government grant income and exclusive of interest income), less property level operating expenses; [added: Adjusted] NOI excludes all other financial statement amounts included in net income (loss) as presented in Note [removed: 15] [added: 16] to the Consolidated Financial Statements.
Adjusted NOI [removed: is calculated as NOI after eliminating] [added: eliminates] the effects of straight-line rents, [removed: DFL non-cash interest,] amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.
[removed: NOI and] Adjusted NOI [removed: are] [added: is] calculated as [removed: NOI and] Adjusted NOI from consolidated properties, plus our share of [removed: NOI and] Adjusted NOI from unconsolidated joint ventures (calculated by applying our actual ownership percentage for the period), less noncontrolling interests’ share of [removed: NOI and] Adjusted NOI from consolidated joint ventures (calculated by applying our actual ownership percentage for the period).
[removed: Management utilizes its] [added: We utilize our] share of [removed: NOI and] Adjusted NOI in assessing [removed: its] [added: our] performance as we have various joint ventures that contribute to [removed: its] [added: our] performance.
Our share of [removed: NOI and] Adjusted NOI should not be considered a substitute for, and should only be considered together with and as a supplement to, our financial information presented in accordance with GAAP.
Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes [removed: NOI and] Adjusted NOI [removed: are] [added: is an] important supplemental [removed: measures] [added: measure] because [removed: they provide] [added: it provides] relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and [removed: present] [added: presents] them on an unlevered basis.
We use [removed: NOI and] Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our [added: Merger-Combined] Same-Store [removed: (“SS”)] [added: (“Merger-Combined SS”)] performance, as described below.
We believe that net income (loss) is the most directly comparable GAAP measure to [removed: NOI and] Adjusted NOI.
[removed: NOI and] Adjusted NOI should not be viewed as [added: an] alternative [removed: measures] [added: measure] of operating performance to net income (loss) as defined by GAAP since [removed: they do] [added: it does] not reflect various excluded items.
Further, our [removed: definitions] [added: definition] of [removed: NOI and] Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating [removed: NOI and] Adjusted NOI.
For [removed: a reconciliation of NOI and] [added: further information, including information reconciling our] Adjusted NOI [added: for reportable segments] to [removed: net] [added: our] income (loss) [removed: by segment,] [added: before income taxes and equity income (loss) from unconsolidated joint ventures,] refer to Note [removed: 15] [added: 16] to the Consolidated Financial Statements.
We generally recover all or a portion of our leased outpatient medical and lab property expenses through tenant [removed: recoveries.][added: recoveries, which are recognized within rental and related revenues.]
[removed: Same-Store NOI and Adjusted (Cash) NOI] [added: This] information allows [added: our investors, analysts, and] us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments.
We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in [removed: Same-Store NOI and] Adjusted NOI (see [added: Adjusted] NOI definition above for further discussion regarding our use of pro-rata share information and its limitations).
[added: Merger-Combined] Same-Store Adjusted NOI [removed: also] excludes [added: government grant income under the CARES Act,] amortization of deferred revenue from tenant-funded [removed: improvements] [added: improvements,] and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.
A property is removed from [added: Merger-Combined] Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, [removed: a change in reporting structure] or [removed: operator transition has been agreed to, or] a significant tenant relocates from a [added: Merger-Combined] Same-Store property to a [added: Merger-Combined] non Same-Store property and that change results in a corresponding increase in revenue.
We do not report [added: Merger-Combined] Same-Store metrics for our other non-reportable segments.
For a reconciliation of [added: Merger-Combined] Same-Store to total portfolio Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.
We believe [added: Nareit] FFO applicable to common [removed: shares,] [added: shares and] diluted [added: Nareit] FFO applicable to common [removed: shares, and diluted FFO per common share] [added: shares] are important supplemental non-GAAP measures of operating performance for a REIT.
The term [added: Nareit] FFO was designed by the REIT industry to address this issue.
The discussion below contains forward-looking statements that involve risks and uncertainties.
Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in “Item 1A, Risk Factors.” See also “Cautionary Language Regarding Forward-Looking Statements” preceding Part I.
The following discussion and analysis should be read in conjunction with our accompanying, consolidated financial statements and the notes thereto.
While there have been signs that cost pressures are moderating, there can be no assurance that this will continue to be the case.
These events include but are not limited to inflation; interest rates; challenges in the financial markets; and changes in the U.S. political administration, which could affect healthcare policy, labor supply, procurement and construction costs, and economic conditions, among other things.
On March 1, 2024, we completed the Merger with Physicians Realty Trust, which resulted in the acquisition of 299 outpatient medical buildings.
- In April 2024, we exercised our option to buy out four redeemable noncontrolling interests, made aggregate cash payments for the total redemption value of $53 million to the related noncontrolling interest holders, and acquired the redeemable noncontrolling interests associated with these entities.
- During the year ended December 31, 2024, we sold: (i) a portfolio of 61 outpatient medical buildings for $697 million and provided the buyer with a mortgage loan secured by the real estate sold for $419 million, (ii) 14 outpatient medical buildings for $220 million, (iii) a portfolio of seven lab buildings for $180 million, and (iv) a portfolio comprised of a land parcel and various vacant buildings on certain of our CCRC campuses for $12 million.
- In February 2025, we repaid $348 million aggregate principal amount of 3.40% senior unsecured notes at maturity.
*•*During the year ended December 31, 2024, we refinanced one of our existing seller financing loans receivable, extended the maturity date to August 2027, and received aggregate partial principal repayments of $74 million.
*•*During the year ended December 31, 2024, we executed an early lease renewal for approximately 2 million square feet leased by CommonSpirit Health, which is subject to a master agreement, which extended the weighted average lease term of existing leases from July 2027 to December 2035, amended the contractual rents to current market rates, and increased the annual contractual lease escalations from 2.5% to 3.0%.
- In January 2025, we received full repayment of: (i) the $48 million outstanding balance of one of our seller financing loans receivable and (ii) the $15 million outstanding balance of one secured loan with an original maturity of July 2027.
On February 3, 2025, our Board of Directors declared a quarterly common stock cash dividend of $0.305 per share, reflecting an increase from $0.30 to $0.305 per share.
Our operating segments are aggregated into the following reportable segments: (i) outpatient medical, (ii) lab, and (iii) CCRC.
*Adjusted NOI*
As described in Note 16 to the Consolidated Financial Statements, our chief operating decision maker (“CODM”) evaluates the performance of our operating segments based on Adjusted NOI.
Our operating segments are aggregated into reportable segments for which we disclose Total Portfolio Adjusted NOI for our reportable segments.
*Merger-Combined Same-Store Adjusted NOI*
Merger-Combined Same-Store Adjusted NOI includes legacy Physicians Realty Trust properties that met the same-store criteria as if they were owned by the Company for the full analysis period.
Properties are included in Merger-Combined Same-Store once they are fully operating for the entirety of the comparative periods presented.
Management believes that continued reporting of the same-store portfolio for only pre-merger Healthpeak Properties, Inc. offers minimal value to investors who are seeking to understand the operating performance and growth potential of the Combined Company.
The Company was provided access to the underlying financial statements of legacy Physicians Realty Trust (which financial statements have been audited or, in the case of interim periods, reviewed) and other detailed information about each property, such as the acquisition date.
Based on this available information, the Company was able to consistently apply its same-store definition across the combined portfolio.
As a result of the Merger, approximately 97% of the combined portfolio is represented in the Merger-Combined Same-Store presentation for the outpatient medical segment for the year ended December 31, 2024.
For a reconciliation of net income (loss) to Nareit FFO and other relevant disclosures, refer to “Non-GAAP Financial Measures Reconciliations” below.
ventures.
We reflect our share of FFO as Adjusted for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis.
We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO as Adjusted to remove the third-party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods.
All adjustments are reflective of our pro rata share of both our consolidated and unconsolidated joint ventures (reported in “other AFFO adjustments”).
See “Nareit FFO” above for further disclosures regarding our use of pro rata share information and its limitations.
| Nareit FFO | | | | | | 1,092,730 | | | | | | 985,180 | | | | | | | | | | | | | | | | | | 107,550 | | |
| FFO as Adjusted | | | | | | 1,231,868 | | | | | | 978,306 | | | | | | | | | | | | | | | | | | 253,562 | | |
| AFFO | | | | | | 1,140,665 | | | | | | 884,230 | | | | | | | | | | | | | | | | | | 256,435 | | |
- an increase in transaction and merger-related costs, primarily as a result of costs incurred in connection with the Merger;
*•*an increase in interest expense, primarily as a result of: (i) debt assumed as part of the Merger, including $1.25 billion aggregate principal amount of senior unsecured notes, $400 million aggregate principal amount of senior unsecured term loans assumed as part of the Merger (the “2028 Term Loan”), and $128 million aggregate principal amount of mortgage debt and (ii) borrowings under the 2029 Term Loan, which closed in March 2024;
- an increase in impairments and loan loss reserves (recoveries), net, primarily as a result of: (i) impairment charges associated with an asset impaired under the held for sale model and (ii) an increase in loan loss reserves recognized on secured loans and mezzanine loans receivable acquired as part of the Merger;
- an increase in income tax expense primarily as a result of an income tax expense incurred in connection with the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024.
- a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California to a third-party in January 2024; and
- an increase in interest income related to mezzanine and secured loans receivable acquired as part of the Merger and seller financing provided in connection with the disposition of 61 outpatient medical buildings in 2024.
- impairments of depreciable real estate; and
and real estate values generally, including our real estate.
As of February 10, 2023, we are structured as an UPREIT.
This structure provides prospective sellers an alternative for disposing of property that has appreciated in value in a tax-deferred manner to Healthpeak OP and aligns our corporate structure with other publicly traded U.S. real estate investment trusts.
Following the Reorganization, Healthpeak OP is the borrower under, and we are the guarantor of, all of the unsecured debt, which includes the Revolving Facility, Term Loan Facilities (each as defined below), commercial paper program, and senior unsecured notes.
Our guarantee of the senior unsecured notes is full and unconditional and applicable to existing and future senior unsecured notes.
The Reorganization did not have a material impact on our financial position, consolidated financial statements, outstanding debt securities, material debt facilities, or business operations.
In connection with the Mergers, we filed a Registration Statement on Form S-4 with the SEC on December 15, 2023, as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with our respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.
We expect the Mergers to close on March 1, 2024.
Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be direct and indirect subsidiaries of Healthpeak OP, respectively.
Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of our stockholders and the shareholders of Physicians Realty Trust.
- In January 2023, we sold two lab buildings in Durham, North Carolina for $113 million.
*•*In January 2023, we acquired a lab land parcel in Cambridge, Massachusetts for $9 million.
- In March 2023, we sold two outpatient medical buildings for $32 million.
- In April 2023, we acquired the remaining 80% interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $4 million.
- In January 2023, we completed a public offering of $400 million aggregate principal amount of 5.25% senior unsecured notes due 2032.
- In May 2023, we completed a public offering of $350 million aggregate principal amount of 5.25% senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $400 million of senior unsecured notes due 2032 issued in January 2023.
- In December 2023, a mortgage loan secured by one CCRC with a principal balance of $85 million matured and was repaid.
*•*In February 2023, we received a partial principal repayment of $102 million on one secured loan.
*•*In February 2023, we received full repayment of the outstanding balance of one $35 million secured loan.
- In April 2023, we received full repayment of the outstanding balance of one $14 million secured loan.
- In May 2023, we received full repayment of two outstanding secured loans with an aggregate balance of $12 million.
- In October 2023, we received full repayment of the outstanding balance of one $21 million secured loan.
We have other non-reportable segments that are comprised primarily of: (i) an interest in our unconsolidated SWF SH JV and (ii) loans receivable.
*Net Operating Income*
We do not control our unconsolidated joint ventures, and our share of amounts from unconsolidated joint ventures do not represent our legal claim to such items.
We present expenses as operating or general and administrative based on the underlying nature of the expense.
*Same-Store*
Same-Store NOI and Adjusted NOI exclude government grant income under the CARES Act.
Properties are included in Same-Store once they are stabilized for the full period in both comparison periods.
Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date.
Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service.
Properties that experience a change in reporting structure are considered stabilized after 12 months in operations under a consistent reporting structure.
*Funds From Operations (“FFO”)*
FFO encompasses Nareit FFO and FFO as Adjusted, each of which is described in detail below.
*FFO as Adjusted*.
More specifically, recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements (“AFFO capital expenditures”) excludes our share from unconsolidated joint ventures (reported in “other AFFO adjustments”).
| AFFO | | | | | | 840,777 | | | | | | 783,702 | | | | | | | | | | | | | | | | | | 57,075 | | |
- an increase in interest expense, primarily as a result of: (i) senior unsecured notes issued during the first half of 2023, (ii) borrowings under the Term Loan Facilities, which were drawn during the fourth quarter of 2022, and (iii) higher interest rates on the commercial paper program, partially offset by lower borrowings on the commercial paper program;
- a gain on sale associated with the disposition of a hospital under a DFL during the first quarter of 2022;
*•*a decrease in government grant income received under the CARES Act in 2023.
An excerpt. Shown here: 40 of 258 rewritten, 40 of 127 added and 40 of 123 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2024 filing and the FY2023 filing.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
9 rewritten, 1 added, 0 removed, 13 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note [removed: 21] [added: 22] to the Consolidated Financial Statements).
At December 31, [removed: 2023,] [added: 2024,] a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by up to [removed: $18] [added: $53] million.
At December 31, [removed: 2023,] [added: 2024,] our exposure to interest rate risk was primarily on our variable rate debt.
At December 31, [removed: 2023, $142 million of our variable rate mortgage debt and our $500 million Term Loan Facilities were] [added: 2024, we had the following] swapped to fixed rates through interest rate swap [removed: instruments.][added: instruments: (i) the $750 million 2029 Term Loan, (ii) the $500 million 2027 Term Loans, (iii) the $400 million 2028 Term Loan, and (iv) $142 million of variable rate mortgage debt.]
At December 31, [removed: 2023,] [added: 2024,] both the fair value and carrying value of the interest rate swap instruments were [removed: $21] [added: $35] million.
Our remaining variable rate debt at December 31, [removed: 2023] [added: 2024] was comprised of borrowings under our commercial paper program and certain of our mortgage debt.
At December 31, [removed: 2023,] [added: 2024,] a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately [removed: $255] [added: $241] million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately [removed: $272] [added: $259] million.
Assuming a one percentage point increase in the interest rates related to our variable rate debt, and assuming no other changes in the outstanding balance at December 31, [removed: 2023,] [added: 2024,] our annual interest expense would increase by approximately [removed: $7] [added: $3] million.
Lastly, assuming a one percentage point decrease in the interest rates related to our variable rate loans receivable, and assuming no other changes in the outstanding balance at December 31, [removed: 2023,] [added: 2024,] our annual interest income would decrease by approximately [removed: $2] [added: $1] million.
Additionally, at December 31, 2024, a one percentage point increase or decrease in interest rates would change the fair value of our fixed rate loans receivable by approximately $15 million.
Item 1. Business
43 rewritten, 26 added, 23 removed, 213 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that [removed: acquires, develops,] owns, [removed: leases,] [added: operates,] and [removed: manages healthcare] [added: develops high-quality] real estate [removed: across] [added: focused on healthcare discovery and delivery in] the United States (“U.S.”).
[removed: As noted above, we completed our Reorganization on February 10, 2023, and following that date, we] [added: We] hold substantially all of our assets and conduct our operations through [removed: the] [added: our] operating subsidiary, Healthpeak OP, [removed: LLC,] a consolidated subsidiary of which we are the managing member.
Our strategy is to [removed: invest in] [added: own, operate,] and [removed: manage] [added: develop high-quality] real estate focused on healthcare discovery and delivery.
We have a diversified portfolio of high-quality healthcare properties across three core asset classes of [removed: lab,] outpatient medical, [added: lab,] and continuing care retirement community (“CCRC”) real estate.
Under the [removed: lab and] outpatient medical [added: and lab] segments, we [removed: invest through the acquisition, development,] [added: own, operate,] and [removed: management of lab buildings,] [added: develop] outpatient medical buildings, [added: hospitals,] and [removed: hospitals.][added: lab buildings.]
We have other non-reportable segments that are comprised primarily [removed: of loans receivable and] [added: of: (i)] an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH [removed: JV”).][added: JV”) and (ii) loans receivable.]
These non-reportable segments have been presented on [removed: an aggregate] [added: a combined] basis herein.
At December 31, [removed: 2023,] [added: 2024,] our portfolio of investments, including properties in [added: certain of] our unconsolidated joint ventures, consisted of interests in [removed: 477] [added: 697 properties: (i) Outpatient medical – 524 properties; (ii) Lab – 139 properties; (iii) CCRC – 15 properties; and (iv) Other non-reportable – 19] properties.
The following table summarizes information for our reportable [removed: and other non-reportable] segments for the year ended December 31, [removed: 2023] [added: 2024] (dollars in thousands):
[removed: (1)Total] [added: (1)Our Adjusted NOI for our reportable segments, which we also refer to as Total] Portfolio [removed: metrics include] [added: Adjusted NOI for our reportable segments, includes] results of operations from disposed properties through the disposition date.
For a description of our significant activities during [removed: 2023,] [added: 2024,] see “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Company Highlights” in this report.
See Note [removed: 4] [added: 3] to the Consolidated Financial Statements for [removed: further information regarding discontinued operations.][added: additional information.]
*The [removed: Merger Agreement*][added: Merger*]
On [removed: October 29, 2023, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Physicians Realty Trust, Physicians Realty L.P. (the “Physicians Partnership”), and certain of our subsidiaries, pursuant to which, among other things, and through a series of transactions (the “Mergers”), (i)] [added: the Closing Date,] each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares [removed: to be] [added: that were] canceled in accordance with the Merger Agreement) [removed: will be automatically] [added: were] converted into the right to receive 0.674 (the “Exchange Ratio”) shares of our common stock, and [removed: (ii)] each outstanding common unit of the Physicians Partnership [removed: will be automatically] [added: was] converted into [removed: and become] common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.
Our portfolio is focused on [removed: lab and] outpatient medical [added: and lab] buildings, favorable sectors that benefit from the universal desire for improved health.
Our properties are located in well-established geographical markets known for scientific research and drug discovery, including San Francisco [removed: (50%)] [added: (53%)] and San Diego [removed: (23%),] [added: (17%),] California, and Boston, Massachusetts [removed: (25%)] [added: (28%)] (based on total square feet).
At December 31, [removed: 2023, 90%] [added: 2024, 88%] of our lab properties were triple-net leased (based on leased square feet).
The following table provides information about our most significant [removed: lab] [added: outpatient medical] tenant concentration for the year ended December 31, [removed: 2023:][added: 2024:]
Our outpatient medical buildings are typically multi-tenant properties leased to healthcare providers (hospitals and physician practices), with approximately [removed: 87%] [added: 78%] of our outpatient medical buildings located on or adjacent to hospital campuses and [removed: 98%] [added: 96%] affiliated with hospital systems as of December 31, [removed: 2023] [added: 2024] (based on total square feet).
At December 31, [removed: 2023,] [added: 2024,] approximately [removed: 65%] [added: 76%] of our outpatient medical buildings were triple-net leased (based on leased square feet) with the remaining leased under gross or modified gross leases.
| HCA Healthcare, Inc. (HCA) | | | | | | [removed: 23] [added: 15] | | % | | | | [removed: 8] [added: 7] | | % |
At December 31, [removed: 2023,] [added: 2024,] we had the following investments in our other non-reportable segments: (i) our unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets (which we refer to as our SWF SH JV) and (ii) loans receivable.
These laws include: (i) U.S. federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid, or other U.S. federal or state healthcare programs; (ii) U.S. federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid anti-kickback statute, which prohibit or restrict the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services; (iii) U.S. federal and state physician self-referral laws (commonly referred to as the “Stark Law”), [removed: which] [added: which, subject to certain exceptions,] generally prohibit referrals [added: of specifically designated health services] by physicians to entities with which the physician or an immediate family member has a financial relationship; and (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare [removed: services.][added: services and which authorizes the U.S. Department of Health and Human Services to impose monetary penalties for certain fraudulent acts.]
These laws are enforced by a variety of federal, state, and local agencies and in the U.S. can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring *qui tam* or “whistleblower” [removed: actions.][added: actions, in which individuals have tremendous financial gain in bringing a whistleblower claim as federal and state false claim acts provide that individuals receive between 15% and 30% of the money recouped.]
Additionally, facilities [removed: will be] [added: are] required to disclose whether any entity on the enrollment form is a private equity company or REIT.
CMS [removed: will make] [added: makes] the information publicly available.
We believe that [removed: ESG] [added: corporate impact] initiatives are a vital part of corporate responsibility, which supports our primary goal of increasing stockholder value through profitable growth.
We continue to advance our commitment to sustainability, with a focus on achieving goals in each of the [removed: ESG] [added: corporate impact] dimensions.
Our Board of Directors oversees [removed: ESG] [added: corporate impact] matters, with the Nominating and Corporate Governance Committee overseeing sustainability and corporate governance matters, the Audit Committee overseeing risk management, and the Compensation and Human Capital Committee overseeing human capital management.
We use an integrated approach to [removed: ESG] [added: corporate impact] throughout our business to identify risks and opportunities, capture efficiencies and cost savings, and report on the issues most relevant to stakeholders.
Our recent [removed: ESG] [added: corporate impact] highlights include:
- Reported a reduction of [removed: 4.2%] [added: 2.1%] in Scope 1 and Scope 2 greenhouse gas emissions (“GHG”) in [removed: 2022] [added: 2023] compared to [removed: 2021] [added: 2022] on a like-for-like comparative basis (as defined below)
- [removed: 4] [added: Obtained 6 new] LEED [removed: certifications and 132] [added: certifications, 19] new ENERGY STAR [removed: certifications obtained] [added: certifications, and 150 ENERGY STAR recertifications] in [removed: 2023][added: 2024]
- Named an ENERGY STAR Partner of the Year [added: for Sustained Excellence] in [removed: 2023,] [added: 2024,] marking our [removed: third] [added: fourth] time receiving the [added: Partner of the Year] award [added: and first time being recognized for Sustained Excellence]
- Received a Green Star rating from the Global Real Estate Sustainability Benchmark (“GRESB”) for the [removed: twelfth] [added: thirteenth] consecutive year, recognizing [removed: top ESG] [added: leading sustainability] performance in our sector
- Named to *Newsweek*’s America’s Most Responsible Companies list for the [removed: fifth] [added: sixth] consecutive year
- Named a constituent in the FTSE4Good Index for the [removed: twelfth] [added: thirteenth] consecutive year
- Named a constituent in the S&P Global Dow Jones Sustainability World Index for the [removed: fourth] [added: fifth] time and S&P Global North America Dow Jones Sustainability Index for the [removed: eleventh] [added: twelfth] consecutive year
For additional information regarding our [removed: ESG] [added: corporate impact] initiatives, methodologies, and approach to climate change, please visit our website at [removed: www.healthpeak.com/ESG.][added: www.healthpeak.com/corporate-impact.]
Our employees represent our greatest asset, and as of December 31, [removed: 2023,] [added: 2024,] we had [removed: 193] [added: 387] full-time employees.
In 2023, we completed our corporate reorganization (the “Reorganization”) into an umbrella partnership REIT (“UPREIT”).
We are headquartered in Denver, Colorado, with additional corporate offices in California, Tennessee, Wisconsin, and Massachusetts and property management offices in several locations throughout the U.S.
On March 1, 2024 (the “Closing Date”), pursuant to the Agreement and Plan of Merger dated October 29, 2023 (the “Merger Agreement”), by and among us, DOC DR Holdco, LLC, one of our wholly owned subsidiaries (“DOC DR Holdco”), DOC DR, LLC, a wholly owned subsidiary of Healthpeak OP (“DOC DR OP Sub”), Physicians Realty Trust, Physicians Realty L.P. (the “Physicians Partnership”): (i) Physicians Realty Trust merged with and into DOC DR Holdco (the “Company Merger”), with DOC DR Holdco surviving as our wholly owned subsidiary (the “Company Surviving Entity”); (ii) immediately following the effectiveness of the Company Merger, we contributed all of the outstanding equity interests in the Company Surviving Entity to Healthpeak OP (the “Contribution”); and (iii) immediately following the Contribution, Physicians Partnership merged with and into DOC DR OP Sub (the “Partnership Merger” and, together with the Company Merger, the “Merger”), with DOC DR OP Sub surviving as a subsidiary of Healthpeak OP.
Subsequent to the Closing Date, the “Combined Company” means Healthpeak and its subsidiaries.
As a result of the Merger, we acquired 299 outpatient medical buildings.
| Segment | | | | | | Adjusted NOI by Reportable Segment(1) | | |
| Outpatient medical | | | | | | $ | 748,730 | |
| Lab | | | | | | 590,606 | | |
| CCRC | | | | | | 136,104 | | |
See Note 16 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by reportable segment to income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures.
See our Segment Analysis below for additional information.
| CommonSpirit Health | | | | | | 6 | | % | | | | 3 | | % |
During the year ended December 31, 2024, we had various other outpatient medical tenants that each represented 1% or less of total revenues.
During the year ended December 31, 2024, we had various lab tenants that each represented 1% or less of total revenues.
Additionally, violations of false claims acts can result in treble damages.
Investigation by a federal or state governmental body for violation of fraud and abuse laws or imposition of any of these penalties upon one of our operators could jeopardize that operator’s business, reputation, and ability to operate.
Further, as reliance on technology has increased, so have the risks posed to those systems.
Parties that provide us with services essential to our operations must continuously monitor and develop their networks and information technology to prevent, detect, address, and mitigate the risk of unauthorized access, misuse, computer viruses, and social engineering, such as phishing.
Our tenants and management companies are continuously working, including with the aid of third-party service providers, to install new, and to upgrade existing, network and information technology systems, to create processes for risk assessment, testing, prioritization, remediation, risk acceptance, and reporting, and to provide awareness training around phishing, malware, and other cyber risks to ensure that our partners that provide us with services essential to our operations are protected against cyber risks and security breaches and that we are also therefore so protected.
However, these upgrades, processes, new technology, and training may not be sufficient to protect us from all risks.
Even the most well protected information, networks, systems, and facilities remain potentially vulnerable because the techniques and technologies used in attempted attacks and intrusions evolve and generally are not recognized until launched against a target.
In some cases, attempted attacks and intrusions are designed not to be detected and, in fact, may not be detected.
Changes in these laws and regulations could negatively affect the ability of our tenants to make lease payments to us.
In some states, healthcare facilities are subject to various state certificate of need (“CON”) laws requiring governmental approval prior to the development or expansion of healthcare facilities and services.
State CON laws often materially impact the ability of competitors to enter into the marketplace of our facilities and the repeal of CON laws could allow competitors to freely operate in previously closed markets.
Sustainability and Corporate Impact
Our corporate headquarters are located in Denver, Colorado, and we have additional offices in California, Tennessee, and Massachusetts.
| Segment | | | | | | Total Portfolio Adjusted NOI(1) | | | | | | Percentage of Total Portfolio Adjusted NOI(1) | | | | | | Number of Properties | | |
| Lab | | | | | | $ | 617,541 | | | | | 51.3 | | % | | | | 146 | | |
| Outpatient medical | | | | | | 452,725 | | | | | | 37.6 | | % | | | | 297 | | |
| CCRC | | | | | | 112,511 | | | | | | 9.3 | | % | | | | 15 | | |
| Other non-reportable | | | | | | 22,210 | | | | | | 1.8 | | % | | | | 19 | | |
| | | | | | | $ | 1,204,987 | | | | | 100.0 | | % | | | | 477 | | |
See “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for additional information regarding Adjusted NOI and see Note 15 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by segment to net income (loss).
In 2020, we concluded that the dispositions of our senior housing triple-net and senior housing operating property (“SHOP”) portfolios represented a strategic shift that had a major effect on our operations and financial results.
Therefore, the results of senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein.
Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be direct and indirect subsidiaries of Healthpeak OP, respectively.
In connection with the Mergers, we filed a Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”) on December 15, 2023, as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with our respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.
Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of our stockholders and the shareholders of Physicians Realty Trust.
We expect the Mergers to close on March 1, 2024.
If the Mergers are not consummated by July 31, 2024 (unless extended under certain circumstances), either we or Physicians Realty Trust may terminate the Merger Agreement.
Our strategy is to invest in and manage real estate focused on healthcare discovery and delivery.
| Tenants | | | | | | Percentage of Segment Revenues | | | | | | Percentage of Total Revenues | | |
| Amgen, Inc. | | | | | | 6 | | % | | | | 2 | | % |
The following table provides information about our most significant outpatient medical tenant concentration for the year ended December 31, 2023:
Sustainability
- Named to CDP’s Leadership band for our climate disclosure for the eleventh consecutive year, most recently with a score of “A-” in 2023
- Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by *IR Magazine* and *Governance Intelligence*
- Included in *Fortune*’s Best Workplaces in Real Estate list for the second consecutive year
An excerpt. Shown here: 40 of 43 rewritten, all 26 added and all 23 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2024 filing and the FY2023 filing.
Item 3. Legal Proceedings
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
See the “Legal Proceedings” section of Note [removed: 11] [added: 12] to the Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 3.
Cover and table of contents
45 rewritten, 18 added, 20 removed, 94 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
For the fiscal year ended December 31, [removed: 2023][added: 2024]
| Common Stock, $1.00 par value | | | [removed: PEAK] [added: DOC] | | | New York Stock Exchange | | |
State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: [removed: $9.2] [added: $11.8] billion.
As of [removed: February 7, 2024,] [added: January 31, 2025,] there were [removed: 547,172,983] [added: 699,564,637] shares of the registrant’s $1.00 par value common stock outstanding.
Portions of the definitive Proxy Statement for the registrant’s [removed: 2024] [added: 2025] Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, [removed: 2023,] [added: 2024,] have been incorporated by reference into Part III of this Report.
For the Fiscal Year Ended December 31, [removed: 2023][added: 2024]
| [Cautionary Language Regarding Forward-Looking [removed: Statements](#i39cdee5f0c374353affc19f158b4853c_10)] [added: Statements](#id87c1e19981e404fb2b458e86ff35366_10)] | | | | | | [removed: [1](#i39cdee5f0c374353affc19f158b4853c_10)] [added: [1](#id87c1e19981e404fb2b458e86ff35366_10)] | | |
| [Risk Factors [removed: Summary](#i39cdee5f0c374353affc19f158b4853c_13)] [added: Summary](#id87c1e19981e404fb2b458e86ff35366_13)] | | | | | | [removed: [1](#i39cdee5f0c374353affc19f158b4853c_13)] [added: [1](#id87c1e19981e404fb2b458e86ff35366_13)] | | |
| [Important Information Regarding Our Disclosure to [removed: Investors](#i39cdee5f0c374353affc19f158b4853c_2048)] [added: Investors](#id87c1e19981e404fb2b458e86ff35366_16)] | | | | | | [removed: [3](#i39cdee5f0c374353affc19f158b4853c_2048)] [added: [3](#id87c1e19981e404fb2b458e86ff35366_16)] | | |
| [Item [removed: 1.](#i39cdee5f0c374353affc19f158b4853c_19)] [added: 1.](#id87c1e19981e404fb2b458e86ff35366_22)] | | | [removed: [Business](#i39cdee5f0c374353affc19f158b4853c_19)] [added: [Business](#id87c1e19981e404fb2b458e86ff35366_22)] | | | [removed: [4](#i39cdee5f0c374353affc19f158b4853c_19)] [added: [4](#id87c1e19981e404fb2b458e86ff35366_22)] | | |
| [Item [removed: 1A.](#i39cdee5f0c374353affc19f158b4853c_22)] [added: 1A.](#id87c1e19981e404fb2b458e86ff35366_25)] | | | [Risk [removed: Factors](#i39cdee5f0c374353affc19f158b4853c_22)] [added: Factors](#id87c1e19981e404fb2b458e86ff35366_25)] | | | [removed: [14](#i39cdee5f0c374353affc19f158b4853c_22)] [added: [14](#id87c1e19981e404fb2b458e86ff35366_25)] | | |
| [Item [removed: 1B.](#i39cdee5f0c374353affc19f158b4853c_25)] [added: 1B.](#id87c1e19981e404fb2b458e86ff35366_28)] | | | [Unresolved Staff [removed: Comments](#i39cdee5f0c374353affc19f158b4853c_25)] [added: Comments](#id87c1e19981e404fb2b458e86ff35366_28)] | | | [removed: [41](#i39cdee5f0c374353affc19f158b4853c_25)] [added: [38](#id87c1e19981e404fb2b458e86ff35366_28)] | | |
| [Item [removed: 2.](#i39cdee5f0c374353affc19f158b4853c_28)] [added: 2.](#id87c1e19981e404fb2b458e86ff35366_34)] | | | [removed: [Properties](#i39cdee5f0c374353affc19f158b4853c_28)] [added: [Properties](#id87c1e19981e404fb2b458e86ff35366_34)] | | | [removed: [42](#i39cdee5f0c374353affc19f158b4853c_28)] [added: [39](#id87c1e19981e404fb2b458e86ff35366_34)] | | |
| [Item [removed: 3.](#i39cdee5f0c374353affc19f158b4853c_31)] [added: 3.](#id87c1e19981e404fb2b458e86ff35366_37)] | | | [Legal [removed: Proceedings](#i39cdee5f0c374353affc19f158b4853c_31)] [added: Proceedings](#id87c1e19981e404fb2b458e86ff35366_37)] | | | [removed: [45](#i39cdee5f0c374353affc19f158b4853c_31)] [added: [42](#id87c1e19981e404fb2b458e86ff35366_37)] | | |
| [Item [removed: 4.](#i39cdee5f0c374353affc19f158b4853c_34)] [added: 4.](#id87c1e19981e404fb2b458e86ff35366_40)] | | | [Mine Safety [removed: Disclosures](#i39cdee5f0c374353affc19f158b4853c_34)] [added: Disclosures](#id87c1e19981e404fb2b458e86ff35366_40)] | | | [removed: [45](#i39cdee5f0c374353affc19f158b4853c_34)] [added: [42](#id87c1e19981e404fb2b458e86ff35366_40)] | | |
| [Item [removed: 5.](#i39cdee5f0c374353affc19f158b4853c_40)] [added: 5.](#id87c1e19981e404fb2b458e86ff35366_46)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i39cdee5f0c374353affc19f158b4853c_40)] [added: Securities](#id87c1e19981e404fb2b458e86ff35366_46)] | | | [removed: [46](#i39cdee5f0c374353affc19f158b4853c_40)] [added: [43](#id87c1e19981e404fb2b458e86ff35366_46)] | | |
| [Item [removed: 6.](#i39cdee5f0c374353affc19f158b4853c_43)] [added: 6.](#id87c1e19981e404fb2b458e86ff35366_49)] | | | [removed: [\[Reserved\]](#i39cdee5f0c374353affc19f158b4853c_43)] [added: [\[Reserved\]](#id87c1e19981e404fb2b458e86ff35366_49)] | | | [removed: [49](#i39cdee5f0c374353affc19f158b4853c_43)] [added: [46](#id87c1e19981e404fb2b458e86ff35366_49)] | | |
| [Item [removed: 7.](#i39cdee5f0c374353affc19f158b4853c_46)] [added: 7.](#id87c1e19981e404fb2b458e86ff35366_52)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i39cdee5f0c374353affc19f158b4853c_46)] [added: Operations](#id87c1e19981e404fb2b458e86ff35366_52)] | | | [removed: [49](#i39cdee5f0c374353affc19f158b4853c_46)] [added: [46](#id87c1e19981e404fb2b458e86ff35366_52)] | | |
| [Item [removed: 7A.](#i39cdee5f0c374353affc19f158b4853c_94)] [added: 7A.](#id87c1e19981e404fb2b458e86ff35366_100)] | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#i39cdee5f0c374353affc19f158b4853c_94)] [added: Risk](#id87c1e19981e404fb2b458e86ff35366_100)] | | | [removed: [68](#i39cdee5f0c374353affc19f158b4853c_94)] [added: [65](#id87c1e19981e404fb2b458e86ff35366_100)] | | |
| [Item [removed: 8.](#i39cdee5f0c374353affc19f158b4853c_97)] [added: 8.](#id87c1e19981e404fb2b458e86ff35366_103)] | | | [Financial Statements and Supplementary [removed: Data](#i39cdee5f0c374353affc19f158b4853c_97)] [added: Data](#id87c1e19981e404fb2b458e86ff35366_103)] | | | [removed: [69](#i39cdee5f0c374353affc19f158b4853c_97)] [added: [67](#id87c1e19981e404fb2b458e86ff35366_103)] | | |
| [Item [removed: 9.](#i39cdee5f0c374353affc19f158b4853c_214)] [added: 9.](#id87c1e19981e404fb2b458e86ff35366_217)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i39cdee5f0c374353affc19f158b4853c_214)] [added: Disclosure](#id87c1e19981e404fb2b458e86ff35366_217)] | | | [removed: [136](#i39cdee5f0c374353affc19f158b4853c_214)] [added: [142](#id87c1e19981e404fb2b458e86ff35366_217)] | | |
| [Item [removed: 9A.](#i39cdee5f0c374353affc19f158b4853c_217)] [added: 9A.](#id87c1e19981e404fb2b458e86ff35366_220)] | | | [Controls and [removed: Procedures](#i39cdee5f0c374353affc19f158b4853c_217)] [added: Procedures](#id87c1e19981e404fb2b458e86ff35366_220)] | | | [removed: [136](#i39cdee5f0c374353affc19f158b4853c_217)] [added: [142](#id87c1e19981e404fb2b458e86ff35366_220)] | | |
| [Item [removed: 9B.](#i39cdee5f0c374353affc19f158b4853c_223)] [added: 9B.](#id87c1e19981e404fb2b458e86ff35366_226)] | | | [Other [removed: Information](#i39cdee5f0c374353affc19f158b4853c_223)] [added: Information](#id87c1e19981e404fb2b458e86ff35366_226)] | | | [removed: [138](#i39cdee5f0c374353affc19f158b4853c_223)] [added: [144](#id87c1e19981e404fb2b458e86ff35366_226)] | | |
| [Item [removed: 9C.](#i39cdee5f0c374353affc19f158b4853c_226)] [added: 9C.](#id87c1e19981e404fb2b458e86ff35366_229)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i39cdee5f0c374353affc19f158b4853c_226)] [added: Inspections](#id87c1e19981e404fb2b458e86ff35366_229)] | | | [removed: [138](#i39cdee5f0c374353affc19f158b4853c_226)] [added: [144](#id87c1e19981e404fb2b458e86ff35366_229)] | | |
| [Item [removed: 10.](#i39cdee5f0c374353affc19f158b4853c_232)] [added: 10.](#id87c1e19981e404fb2b458e86ff35366_235)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i39cdee5f0c374353affc19f158b4853c_232)] [added: Governance](#id87c1e19981e404fb2b458e86ff35366_235)] | | | [removed: [139](#i39cdee5f0c374353affc19f158b4853c_232)] [added: [145](#id87c1e19981e404fb2b458e86ff35366_235)] | | |
| [Item [removed: 11.](#i39cdee5f0c374353affc19f158b4853c_235)] [added: 11.](#id87c1e19981e404fb2b458e86ff35366_238)] | | | [Executive [removed: Compensation](#i39cdee5f0c374353affc19f158b4853c_235)] [added: Compensation](#id87c1e19981e404fb2b458e86ff35366_238)] | | | [removed: [139](#i39cdee5f0c374353affc19f158b4853c_235)] [added: [145](#id87c1e19981e404fb2b458e86ff35366_238)] | | |
| [Item [removed: 12.](#i39cdee5f0c374353affc19f158b4853c_238)] [added: 12.](#id87c1e19981e404fb2b458e86ff35366_241)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i39cdee5f0c374353affc19f158b4853c_238)] [added: Matters](#id87c1e19981e404fb2b458e86ff35366_241)] | | | [removed: [139](#i39cdee5f0c374353affc19f158b4853c_238)] [added: [145](#id87c1e19981e404fb2b458e86ff35366_241)] | | |
| [Item [removed: 13.](#i39cdee5f0c374353affc19f158b4853c_241)] [added: 13.](#id87c1e19981e404fb2b458e86ff35366_244)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i39cdee5f0c374353affc19f158b4853c_241)] [added: Independence](#id87c1e19981e404fb2b458e86ff35366_244)] | | | [removed: [139](#i39cdee5f0c374353affc19f158b4853c_241)] [added: [145](#id87c1e19981e404fb2b458e86ff35366_244)] | | |
| [Item [removed: 14.](#i39cdee5f0c374353affc19f158b4853c_244)] [added: 14.](#id87c1e19981e404fb2b458e86ff35366_247)] | | | [Principal Accountant Fees and [removed: Services](#i39cdee5f0c374353affc19f158b4853c_244)] [added: Services](#id87c1e19981e404fb2b458e86ff35366_247)] | | | [removed: [139](#i39cdee5f0c374353affc19f158b4853c_244)] [added: [145](#id87c1e19981e404fb2b458e86ff35366_247)] | | |
| [Item [removed: 15.](#i39cdee5f0c374353affc19f158b4853c_250)] [added: 15.](#id87c1e19981e404fb2b458e86ff35366_253)] | | | [Exhibits and Financial Statement [removed: Schedules](#i39cdee5f0c374353affc19f158b4853c_250)] [added: Schedules](#id87c1e19981e404fb2b458e86ff35366_253)] | | | [removed: [140](#i39cdee5f0c374353affc19f158b4853c_250)] [added: [146](#id87c1e19981e404fb2b458e86ff35366_253)] | | |
| [Item [removed: 16.](#i39cdee5f0c374353affc19f158b4853c_256)] [added: 16.](#id87c1e19981e404fb2b458e86ff35366_259)] | | | [Form 10-K [removed: Summary](#i39cdee5f0c374353affc19f158b4853c_256)] [added: Summary](#id87c1e19981e404fb2b458e86ff35366_259)] | | | [removed: [144](#i39cdee5f0c374353affc19f158b4853c_256)] [added: [151](#id87c1e19981e404fb2b458e86ff35366_259)] | | |
You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below under [removed: “Summary Risk Factors”] [added: “Risk Factors Summary”] and in “Item 1A, Risk Factors” in this report.
Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Annual [removed: Report.][added: Report, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report.]
- our ability to [added: successfully] integrate [removed: the] [added: our] operations [removed: of the Company and] [added: with] Physicians Realty Trust [removed: successfully] and realize the anticipated synergies [added: of the Merger (as defined below)] and [removed: other] benefits of [removed: the Mergers or do so within the anticipated time frame;][added: property management internalization;]
- [added: changes within the life science industry, and] significant regulation, funding requirements, and uncertainty faced by our lab tenants;
- operational risks associated with [added: our senior housing properties managed by] third [removed: party management contracts,] [added: parties,] including [removed: the additional regulation and liabilities of] our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”);
- our use of [removed: fixed] rent [removed: escalators,] [added: escalators or] contingent rent [removed: provisions, and/or rent escalators based on the Consumer Price Index;][added: provisions in our leases;]
- our ability to [removed: foreclose or] exercise rights on collateral securing our real estate-related loans;
- our ability to successfully integrate or operate [removed: acquisitions;][added: acquisitions and/or internalize property management;]
- the potential impact [removed: on us and our tenants, operators, and borrowers from] [added: of unfavorable resolution of] litigation [removed: matters, including] [added: or disputes and resulting] rising liability and insurance costs;
| [Part I](#id87c1e19981e404fb2b458e86ff35366_19) | | | | | | [4](#id87c1e19981e404fb2b458e86ff35366_19) | | |
| [Item 1C.](#id87c1e19981e404fb2b458e86ff35366_31) | | | [Cybersecurity](#id87c1e19981e404fb2b458e86ff35366_31) | | | [38](#id87c1e19981e404fb2b458e86ff35366_31) | | |
| [Part II](#id87c1e19981e404fb2b458e86ff35366_43) | | | | | | [43](#id87c1e19981e404fb2b458e86ff35366_43) | | |
| [Part III](#id87c1e19981e404fb2b458e86ff35366_232) | | | | | | [145](#id87c1e19981e404fb2b458e86ff35366_232) | | |
| [Part IV](#id87c1e19981e404fb2b458e86ff35366_250) | | | | | | [146](#id87c1e19981e404fb2b458e86ff35366_250) | | |
| | | | [Signatures](#id87c1e19981e404fb2b458e86ff35366_262) | | | [152](#id87c1e19981e404fb2b458e86ff35366_262) | | |
- macroeconomic trends that may increase construction, labor, and other operating costs;
- our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion;
- uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses;
- the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors;
- increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities;
- the availability of external capital on acceptable terms or at all;
- an increase in our level of indebtedness;
- covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants;
- volatility in the market price and trading volume of our common stock;
- adverse changes in our credit ratings;
- changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate;
- tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels;
| [Part I](#i39cdee5f0c374353affc19f158b4853c_16) | | | | | | [4](#i39cdee5f0c374353affc19f158b4853c_16) | | |
| [I](#i39cdee5f0c374353affc19f158b4853c_2012)[tem 1C.](#i39cdee5f0c374353affc19f158b4853c_2012) | | | [C](#i39cdee5f0c374353affc19f158b4853c_2012)[ybersecurity](#i39cdee5f0c374353affc19f158b4853c_2012) | | | [41](#i39cdee5f0c374353affc19f158b4853c_2012) | | |
| [Part II](#i39cdee5f0c374353affc19f158b4853c_37) | | | | | | [46](#i39cdee5f0c374353affc19f158b4853c_37) | | |
| [Part III](#i39cdee5f0c374353affc19f158b4853c_229) | | | | | | [139](#i39cdee5f0c374353affc19f158b4853c_229) | | |
| [Part IV](#i39cdee5f0c374353affc19f158b4853c_247) | | | | | | [140](#i39cdee5f0c374353affc19f158b4853c_247) | | |
| | | | [Signatures](#i39cdee5f0c374353affc19f158b4853c_259) | | | [145](#i39cdee5f0c374353affc19f158b4853c_259) | | |
*On February 10, 2023, we completed our corporate reorganization (the “Reorganization”) into an umbrella partnership REIT (“UPREIT”).
Substantially all of our business is conducted through Healthpeak OP, LLC (“Healthpeak OP”).
We are the managing member of Healthpeak OP and do not have material assets or liabilities, other than through our investment in Healthpeak OP.*
Forward-looking statements in this Annual Report on Form 10-K include statements regarding the proposed transactions involving Healthpeak and Physicians Realty Trust (as discussed in further detail in this report), including but not limited to, statements about the anticipated benefits of the proposed transactions involving Healthpeak and Physicians Realty Trust, as well as statements regarding future financial and operating results, plans, objectives, expectations, and intentions.
- macroeconomic trends, including inflation, interest rates, construction and labor costs, and unemployment;
- risks associated with the Mergers (as defined below), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all; potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers; and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers;
- changes within the industries in which we operate;
- our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected;
- uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators;
- increased borrowing costs, including due to rising interest rates;
- the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions, and other factors;
- our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness;
- legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services;
- ownership limits in our charter that restrict ownership in our stock;
An excerpt. Shown here: 40 of 45 rewritten, all 18 added and all 20 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2024 filing and the FY2023 filing.
Item 1C. Cybersecurity
2 rewritten, 0 added, 0 removed, 26 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
- a cybersecurity incident response [removed: plan and] [added: plan,] business continuity [removed: plan;][added: plan, and established policies governing cybersecurity risk management at the corporate and property levels;]
This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief [removed: executive] [added: information security] officer of a cybersecurity firm focused on commercial real estate.
Item 2. Properties
24 rewritten, 22 added, 23 removed, 40 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Our strategy is to [removed: invest in] [added: own, operate,] and [removed: manage] [added: develop high-quality] real estate focused on healthcare discovery and delivery.
The following table summarizes our consolidated property investments as of and for the year ended December 31, [removed: 2023] [added: 2024] (square feet and dollars in thousands):
| Facility Location | | | | | | Number of Facilities | | | | | | Capacity(1) | | | | | | Gross Asset Value(2) | | | | | | Real Estate Revenues(3) | | | | | | Operating [removed: Expenses(4)] [added: Expenses] | | |
Excludes gross real estate of [removed: $123] [added: $11] million related to [removed: two lab buildings and] one outpatient medical building classified as held for sale.
(3)Represents the combined amount of rental and related [removed: revenues,] [added: revenues and] resident fees and [removed: services, and government grant income.][added: services.]
The following table summarizes occupancy and average annual rent trends for our consolidated [removed: property and investments held under a direct financing lease (“DFL”)] [added: properties] for the years ended December 31 (average occupied square feet in thousands):
| | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2022] [added: 2023] | | | | | | [removed: 2021] [added: 2022] | | | | | | | | | | | | | | |
| Average occupancy [removed: percentage] [added: percentage(1)] | | | [removed: 98] [added: 92] | | % | | | | [removed: 98] [added: 90] | | % | | | | [removed: 97] [added: 90] | | % | | | | | | | | | | | | |
| Average annual rent per square [removed: foot(1)] [added: foot(2)] | | | $ | [removed: 82] [added: 36] | | | | | $ | [removed: 71] [added: 35] | | | | | $ | [removed: 66] [added: 33] | | | | | | | | | | | | | |
| Average occupied square feet | | | [removed: 10,334] [added: 9,404] | | | | | | [removed: 10,610] [added: 10,334] | | | | | | [removed: 10,143] [added: 10,610] | | | | | | | | | | | | | | |
| *Outpatient [removed: medical(2):*] [added: medical:*] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Average occupancy [removed: percentage] [added: percentage(1)] | | | [removed: 90] [added: 96] | | % | | | | [removed: 90] [added: 98] | | % | | | | [removed: 90] [added: 98] | | % | | | | | | | | | | | | |
| Average annual rent per square [removed: foot(1)] [added: foot(2)] | | | $ | [removed: 35] [added: 87] | | | | | $ | [removed: 33] [added: 82] | | | | | $ | [removed: 31] [added: 71] | | | | | | | | | | | | | |
| Average occupied square feet | | | [removed: 21,337] [added: 32,431] | | | | | | [removed: 21,472] [added: 21,337] | | | | | | [removed: 21,046] [added: 21,472] | | | | | | | | | | | | | | |
| Average occupancy [removed: percentage] [added: percentage(1)] | | | [removed: 84] [added: 85] | | % | | | | [removed: 82] [added: 84] | | % | | | | [removed: 79] [added: 82] | | % | | | | | | | | | | | | |
| Average annual rent per occupied unit(3) | | | $ | [removed: 88,524] [added: 94,103] | | | | | $ | [removed: 84,664] [added: 88,524] | | | | | $ | [removed: 80,391] [added: 84,664] | | | | | | | | | | | | | |
| Average occupied units | | | [removed: 5,960] [added: 6,041] | | | | | | [removed: 5,926] [added: 5,960] | | | | | | [removed: 5,881] [added: 5,926] | | | | | | | | | | | | | | |
[removed: (1)Presented] [added: (2)Presented] as a ratio of revenues comprised of rental and related revenues [removed: and income from DFLs] divided by average occupied square feet and annualized for acquisitions for the year in which they occurred.
Average annual rent excludes termination fees and non-cash revenue adjustments (i.e., straight-line [removed: rents,] [added: rents and] amortization of market lease [removed: intangibles, and DFL non-cash interest).][added: intangibles).]
The following table shows tenant lease expirations for the next 10 years and thereafter at our consolidated properties, assuming that none of the tenants exercise any of their renewal or purchase options, and excludes properties in our CCRC segment and assets held for sale as of December 31, [removed: 2023] [added: 2024] (dollars and square feet in thousands):
| Segment | | | | | | Total | | | | | | [removed: 2024(1) | | | | | | 2025] [added: 2025(1)] | | | | | | 2026 | | | | | | 2027 | | | | | | 2028 | | | | | | 2029 | | | | | | 2030 | | | | | | 2031 | | | | | | 2032 | | | | | | 2033 | | | | | | [added: 2034 | | | | | |] Thereafter | | |
| % of segment base rent | | | | | | 100 | | | | | | [removed: 6] [added: 12] | | | | | | [removed: 8] [added: 13] | | | | | | [removed: 5] [added: 10] | | | | | | 11 | | | | | | [removed: 6] [added: 11] | | | | | | [removed: 8] [added: 7] | | | | | | [removed: 16] [added: 7] | | | | | | [removed: 14] [added: 7] | | | | | | [removed: 9] [added: 6] | | | | | | [removed: 6] [added: 4] | | | | | | [removed: 11] [added: 12] | | |
| % of segment base rent | | | | | | 100 | | | | | | [removed: 16] [added: 6] | | | | | | [removed: 13] [added: 5] | | | | | | [removed: 11] [added: 10] | | | | | | [removed: 9] [added: 7] | | | | | | [removed: 10] [added: 9] | | | | | | [removed: 7] [added: 14] | | | | | | [removed: 7] [added: 12] | | | | | | [removed: 7] [added: 11] | | | | | | [removed: 5] [added: 8] | | | | | | [removed: 5] [added: 9] | | | | | | [removed: 10] [added: 9] | | |
| % of total base rent | | | | | | 100 | | | | | | [removed: 11] [added: 10] | | | | | | 10 | | | | | | [removed: 8] [added: 10] | | | | | | [removed: 10] [added: 9] | | | | | | [removed: 8] [added: 10] | | | | | | [removed: 8] [added: 10] | | | | | | [removed: 11] [added: 9] | | | | | | [removed: 11] [added: 9] | | | | | | 7 | | | | | | [removed: 5] [added: 6] | | | | | | [removed: 11] [added: 10] | | |
| Texas | | | | | | 103 | | | | | | 9,333 | | | | | | $ | 2,103,743 | | | | | $ | 295,840 | | | | | $ | (99,990) | |
| Florida | | | | | | 39 | | | | | | 2,206 | | | | | | 584,475 | | | | | | 72,769 | | | | | | (25,323) | | |
| Pennsylvania | | | | | | 15 | | | | | | 1,613 | | | | | | 456,194 | | | | | | 42,747 | | | | | | (17,205) | | |
| Tennessee | | | | | | 25 | | | | | | 2,348 | | | | | | 441,428 | | | | | | 71,504 | | | | | | (23,695) | | |
| Colorado | | | | | | 23 | | | | | | 1,443 | | | | | | 425,430 | | | | | | 54,562 | | | | | | (32,255) | | |
| Georgia | | | | | | 14 | | | | | | 1,418 | | | | | | 398,723 | | | | | | 43,848 | | | | | | (14,281) | | |
| Other (36 States) | | | | | | 288 | | | | | | 17,682 | | | | | | 4,646,540 | | | | | | 624,474 | | | | | | (193,244) | | |
| *Total outpatient medical* | | | | | | 507 | | | | | | 36,043 | | | | | | $ | 9,056,533 | | | | | $ | 1,205,744 | | | | | $ | (405,993) | |
| California | | | | | | 106 | | | | | | 7,862 | | | | | | $ | 5,919,953 | | | | | $ | 632,860 | | | | | $ | (162,212) | |
| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,838,593 | | | | | | 241,376 | | | | | | (73,290) | | |
| Other (1 State) | | | | | | 4 | | | | | | 240 | | | | | | 54,239 | | | | | | 7,216 | | | | | | (4,118) | | |
| *Total lab* | | | | | | 129 | | | | | | 10,715 | | | | | | $ | 8,812,785 | | | | | $ | 881,452 | | | | | $ | (239,620) | |
| Florida | | | | | | 9 | | | | | | 4,774 | | | | | | $ | 1,395,819 | | | | | $ | 367,604 | | | | | $ | (282,500) | |
| Other (5 States) | | | | | | 6 | | | | | | 2,286 | | | | | | 649,297 | | | | | | 200,871 | | | | | | (146,748) | | |
| *Total CCRC* | | | | | | 15 | | | | | | 7,060 | | | | | | $ | 2,045,116 | | | | | $ | 568,475 | | | | | $ | (429,248) | |
| Total properties | | | | | | 651 | | | | | | | | | | | | $ | 19,914,434 | | | | | $ | 2,655,671 | | | | | $ | (1,074,861) | |
(1)Average occupancy excludes any of the following: (i) developments, (ii) significant redevelopments, (iii) newly completed properties under lease-up, and (iv) properties held for sale.
| Square feet | | | | | | 33,278 | | | | | | 3,788 | | | | | | 4,090 | | | | | | 3,066 | | | | | | 3,930 | | | | | | 3,177 | | | | | | 2,237 | | | | | | 2,590 | | | | | | 2,710 | | | | | | 1,668 | | | | | | 1,494 | | | | | | 4,528 | | |
| Base rent(2) | | | | | | $ | 873,741 | | | | | $ | 104,756 | | | | | $ | 116,522 | | | | | $ | 85,332 | | | | | $ | 96,518 | | | | | $ | 92,462 | | | | | $ | 60,431 | | | | | $ | 65,266 | | | | | $ | 63,952 | | | | | $ | 47,918 | | | | | $ | 38,004 | | | | | $ | 102,580 | |
| Square feet | | | | | | 9,167 | | | | | | 675 | | | | | | 401 | | | | | | 1,030 | | | | | | 694 | | | | | | 844 | | | | | | 1,143 | | | | | | 1,050 | | | | | | 969 | | | | | | 594 | | | | | | 693 | | | | | | 1,074 | | |
| Base rent(2) | | | | | | $ | 572,298 | | | | | $ | 35,987 | | | | | $ | 28,059 | | | | | $ | 55,900 | | | | | $ | 37,850 | | | | | $ | 53,436 | | | | | $ | 79,287 | | | | | $ | 70,497 | | | | | $ | 63,067 | | | | | $ | 47,263 | | | | | $ | 52,233 | | | | | $ | 48,719 | |
| Base rent(2) | | | | | | $ | 1,446,039 | | | | | $ | 140,743 | | | | | $ | 144,581 | | | | | $ | 141,232 | | | | | $ | 134,368 | | | | | $ | 145,898 | | | | | $ | 139,718 | | | | | $ | 135,763 | | | | | $ | 127,019 | | | | | $ | 95,181 | | | | | $ | 90,237 | | | | | $ | 151,299 | |
| California | | | | | | 115 | | | | | | 8,094 | | | | | | $ | 5,869,665 | | | | | $ | 629,657 | | | | | $ | (157,795) | |
| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,795,913 | | | | | | 240,029 | | | | | | (70,259) | | |
| Other (1 State) | | | | | | 4 | | | | | | 240 | | | | | | 54,236 | | | | | | 8,640 | | | | | | (1,576) | | |
| *Total lab* | | | | | | 138 | | | | | | 10,947 | | | | | | $ | 8,719,814 | | | | | $ | 878,326 | | | | | $ | (229,630) | |
| Texas | | | | | | 75 | | | | | | 7,638 | | | | | | $ | 1,549,757 | | | | | $ | 220,805 | | | | | $ | (75,159) | |
| Pennsylvania | | | | | | 4 | | | | | | 1,270 | | | | | | 367,434 | | | | | | 34,321 | | | | | | (15,603) | | |
| Colorado | | | | | | 19 | | | | | | 1,311 | | | | | | 362,822 | | | | | | 47,697 | | | | | | (18,366) | | |
| California | | | | | | 15 | | | | | | 862 | | | | | | 355,026 | | | | | | 40,057 | | | | | | (17,206) | | |
| South Carolina | | | | | | 18 | | | | | | 1,105 | | | | | | 340,073 | | | | | | 27,851 | | | | | | (5,315) | | |
| Florida | | | | | | 25 | | | | | | 1,438 | | | | | | 309,246 | | | | | | 41,609 | | | | | | (14,994) | | |
| Other (29 States) | | | | | | 139 | | | | | | 9,977 | | | | | | 2,586,334 | | | | | | 341,139 | | | | | | (116,489) | | |
| *Total outpatient medical* | | | | | | 295 | | | | | | 23,601 | | | | | | $ | 5,870,692 | | | | | $ | 753,479 | | | | | $ | (263,132) | |
| Florida | | | | | | 9 | | | | | | 4,783 | | | | | | $ | 1,398,609 | | | | | $ | 343,971 | | | | | $ | (275,781) | |
| Other (5 States) | | | | | | 6 | | | | | | 2,314 | | | | | | 631,199 | | | | | | 183,630 | | | | | | (137,691) | | |
| *Total CCRC* | | | | | | 15 | | | | | | 7,097 | | | | | | $ | 2,029,808 | | | | | $ | 527,601 | | | | | $ | (413,472) | |
| Total properties | | | | | | 448 | | | | | | | | | | | | $ | 16,620,314 | | | | | $ | 2,159,406 | | | | | $ | (906,234) | |
(4)Excludes operating expenses related to corporate non-segment assets (see Note 15 to the Consolidated Financial Statements).
(2)During the first quarter of 2022, we sold our remaining hospital under a DFL.
| Square feet | | | | | | 10,303 | | | | | | 537 | | | | | | 1,065 | | | | | | 618 | | | | | | 1,407 | | | | | | 681 | | | | | | 806 | | | | | | 1,334 | | | | | | 1,393 | | | | | | 866 | | | | | | 531 | | | | | | 1,065 | | |
| Base rent(2) | | | | | | $ | 608,770 | | | | | $ | 36,709 | | | | | $ | 50,557 | | | | | $ | 30,694 | | | | | $ | 66,918 | | | | | $ | 36,728 | | | | | $ | 50,104 | | | | | $ | 94,051 | | | | | $ | 84,727 | | | | | $ | 55,504 | | | | | $ | 36,642 | | | | | $ | 66,136 | |
| Square feet | | | | | | 21,414 | | | | | | 2,848 | | | | | | 2,830 | | | | | | 2,049 | | | | | | 1,870 | | | | | | 2,539 | | | | | | 1,419 | | | | | | 1,310 | | | | | | 1,637 | | | | | | 1,357 | | | | | | 918 | | | | | | 2,637 | | |
| Base rent(2) | | | | | | $ | 546,589 | | | | | $ | 85,359 | | | | | $ | 68,994 | | | | | $ | 57,376 | | | | | $ | 51,438 | | | | | $ | 56,996 | | | | | $ | 38,197 | | | | | $ | 36,069 | | | | | $ | 40,803 | | | | | $ | 28,096 | | | | | $ | 27,376 | | | | | $ | 55,885 | |
| Base rent(2) | | | | | | $ | 1,155,359 | | | | | $ | 122,068 | | | | | $ | 119,551 | | | | | $ | 88,070 | | | | | $ | 118,356 | | | | | $ | 93,724 | | | | | $ | 88,301 | | | | | $ | 130,120 | | | | | $ | 125,530 | | | | | $ | 83,600 | | | | | $ | 64,018 | | | | | $ | 122,021 | |
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
22 rewritten, 10 added, 12 removed, 21 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Our common stock is listed on the New York Stock Exchange under the symbol [removed: “PEAK.”][added: “DOC.”]
As of [removed: February 5, 2024,] [added: January 29, 2025,] we had [removed: 6,797] [added: 6,645] stockholders of record, and there were [removed: 283,417] [added: 447,008] beneficial holders of our common stock.
| | | | [removed: 2023] [added: 2020] | | | | | | [added: 2021 | | | | | |] 2022 | | | | | | [removed: 2021] [added: 2023] | | | [added: | | | 2024 | | |]
| Ordinary dividends(1) | | | $ | [removed: 0.909692] [added: 0.720440] | | | | | $ | [removed: 0.872948] [added: 0.909692] | | | | | $ | [removed: 0.152336] [added: 0.872948] | |
| Capital gains(2)(3) | | | [removed: 0.116992] [added: 0.295060] | | | | | | [removed: 0.183208] [added: 0.116992] | | | | | | [removed: 0.379960] [added: 0.183208] | | |
| Nondividend distributions | | | [removed: 0.173316] [added: 0.184500] | | | | | | [removed: 0.143844] [added: 0.173316] | | | | | | [removed: 0.667704] [added: 0.143844] | | |
[removed: (1)For] [added: For] the year ended December 31, 2023, the amount includes $0.882312 of ordinary dividends qualified as business income for purposes of Code Section 199A and $0.027380 of qualified dividend income for purposes of Code Section 1(h)(11).
[removed: For] [added: (1)For] the year ended December 31, [removed: 2021, the amount includes $0.137064] [added: 2024, all $0.720440] of ordinary dividends qualified as business income for purposes of Code Section [removed: 199A and $0.015272 of qualified dividend income for purposes of Code Section 1(h)(11).][added: 199A.]
(2)For the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021,] [added: 2022,] the amount includes [added: $0.215960,] $0.036256, [removed: $0.017760,] and [removed: $0.379960,] [added: $0.017760,] respectively, of unrecaptured Code Section 1250 gain.
Code Section 1061 is generally applicable to direct and indirect holders of “applicable partnership interests.” For the [removed: year] [added: years] ended December 31, [added: 2024 and] 2023, the “One Year Amounts” and “Three Year Amounts” are each zero, since all capital gains relate to Code Section 1231 gains.
(3)For the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021,] [added: 2022,] 100%, [removed: 10.3292%, and] 100%, [added: and 10.3292%,] respectively, of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.
On [removed: January 31, 2024, we announced that] [added: February 3, 2025,] our Board of Directors declared a quarterly common stock cash dividend of [added: $0.305 per share, reflecting an increase from] $0.30 [added: to $0.305] per share.
The common stock [added: cash] dividend will be paid on February 26, [removed: 2024] [added: 2025] to stockholders of record as of the close of business on February 14, [removed: 2024.][added: 2025.]
The following table sets forth information with respect to purchases of our common stock made by or on our behalf during the three months ended December 31, [removed: 2023.][added: 2024.]
(1)On [removed: August 1, 2022,] [added: July 24, 2024,] our Board of Directors approved [removed: a share repurchase program] [added: the 2024 Share Repurchase Program] under which we may acquire shares of our common stock in the open market [added: or other similar purchase techniques (including in compliance with the safe harbor provisions of Rule 10b-18 under the Exchange Act or pursuant to one or more plans adopted under Rule 10b5-1 promulgated under the Exchange Act),] up to an aggregate purchase price of $500 [removed: million (the “Share Repurchase Program”).][added: million.]
Purchases of common stock under the [added: 2024] Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities.
The [added: 2024] Share Repurchase Program expires in [removed: August 2024] [added: July 2026] and may be suspended or terminated at any time without prior notice.
[removed: During the year ended December 31, 2023, there were no repurchases; therefore,] [added: Therefore,] at December 31, [removed: 2023, $444] [added: 2024, $500] million of [removed: our] [added: the Company’s] common stock remained available for repurchase under the [added: 2024] Share Repurchase Program.
The graph and table below compare the cumulative total return of Healthpeak, the S&P 500 Index, and the Equity REIT Index of Nareit, from January 1, [removed: 2019] [added: 2020] to December 31, [removed: 2023.][added: 2024.]
Total cumulative return is based on a $100 investment in Healthpeak common stock and in each of the indices at the close of trading on December 31, [removed: 2018] [added: 2019] and assumes quarterly reinvestment of dividends before consideration of income taxes.
(JANUARY 1, [removed: 2019] [added: 2020] = $100)
[removed: ][added: ]
| | | | 2024 | | | | | | 2023 | | | | | | 2022 | | |
| October 1-31, 2024 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 500,000,000 | |
| November 1-30, 2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | 500,000,000 | | |
| December 1-31, 2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | 500,000,000 | | |
| | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 500,000,000 | |
As of December 31, 2024, no shares have been repurchased under the 2024 Share Repurchase Program.
JANUARY 1, 2020–DECEMBER 31, 2024
| FTSE Nareit Equity REIT Index | | | $ | 94.88 | | | | | $ | 134.06 | | | | | $ | 100.62 | | | | | $ | 112.04 | | | | | $ | 117.56 | |
| S&P 500 | | | 118.39 | | | | | | 152.34 | | | | | | 124.73 | | | | | | 157.48 | | | | | | 196.85 | | |
| Healthpeak Properties, Inc. | | | 92.33 | | | | | | 114.25 | | | | | | 82.83 | | | | | | 69.24 | | | | | | 75.37 | | |
For the year ended December 31, 2021, the “One Year Amounts” and “Three Year Amounts” are each zero, since all capital gains relate to Code Section 1231 gains.
| October 1-31, 2023 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 444,018,701 | |
| November 1-30, 2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | 444,018,701 | | |
| December 1-31, 2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | 444,018,701 | | |
| | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 444,018,701 | |
During the year ended December 31, 2022, we repurchased 2.1 million shares of our common stock at a weighted average price of $27.16 per share.
Amounts do not include the shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations as discussed in footnote 1.
JANUARY 1, 2019–DECEMBER 31, 2023
| | | | 2019 | | | | | | 2020 | | | | | | 2021 | | | | | | 2022 | | | | | | 2023 | | |
| FTSE Nareit Equity REIT Index | | | $ | 128.66 | | | | | $ | 122.07 | | | | | $ | 172.49 | | | | | $ | 129.45 | | | | | $ | 144.16 | |
| S&P 500 | | | 131.47 | | | | | | 155.65 | | | | | | 200.29 | | | | | | 163.98 | | | | | | 207.04 | | |
| Healthpeak Properties, Inc. | | | 129.11 | | | | | | 119.21 | | | | | | 147.52 | | | | | | 106.94 | | | | | | 89.40 | | |
Item 8. Financial Statements and Supplementary Data
1,082 rewritten, 761 added, 396 removed, 863 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | | | [removed: [70](#i39cdee5f0c374353affc19f158b4853c_100)] [added: [68](#id87c1e19981e404fb2b458e86ff35366_106)] | | |
| [Consolidated Balance [removed: Sheets—](#i39cdee5f0c374353affc19f158b4853c_103)December] [added: Sheets—](#id87c1e19981e404fb2b458e86ff35366_109)December] 31, [added: 2024 [and](#id87c1e19981e404fb2b458e86ff35366_109)] 2023 [removed: [and](#i39cdee5f0c374353affc19f158b4853c_103) 2022] | | | [removed: [72](#i39cdee5f0c374353affc19f158b4853c_103)] [added: [70](#id87c1e19981e404fb2b458e86ff35366_109)] | | |
| [Consolidated Statements of Operations—for the years [removed: ended](#i39cdee5f0c374353affc19f158b4853c_106)] [added: ended](#id87c1e19981e404fb2b458e86ff35366_112)] December 31, [removed: 2023[,](#i39cdee5f0c374353affc19f158b4853c_106) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_106) 2021] [added: 2024[,](#id87c1e19981e404fb2b458e86ff35366_112) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_112) 2022] | | | [removed: [73](#i39cdee5f0c374353affc19f158b4853c_106)] [added: [71](#id87c1e19981e404fb2b458e86ff35366_112)] | | |
| [Consolidated Statements of Comprehensive Income (Loss)—for the years [removed: ended](#i39cdee5f0c374353affc19f158b4853c_109)] [added: ended](#id87c1e19981e404fb2b458e86ff35366_115)] December 31, [removed: 2023[,](#i39cdee5f0c374353affc19f158b4853c_109) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_109) 2021] [added: 2024[,](#id87c1e19981e404fb2b458e86ff35366_115) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_115) 2022] | | | [removed: [74](#i39cdee5f0c374353affc19f158b4853c_109)] [added: [72](#id87c1e19981e404fb2b458e86ff35366_115)] | | |
| [Consolidated Statements of Equity and Redeemable Noncontrolling Interests—for the years [removed: ended](#i39cdee5f0c374353affc19f158b4853c_112)] [added: ended](#id87c1e19981e404fb2b458e86ff35366_118)] December 31, [removed: 2023[,](#i39cdee5f0c374353affc19f158b4853c_112) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_112) 2021] [added: 2024[,](#id87c1e19981e404fb2b458e86ff35366_118) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_118) 2022] | | | [removed: [75](#i39cdee5f0c374353affc19f158b4853c_112)] [added: [73](#id87c1e19981e404fb2b458e86ff35366_118)] | | |
| [Consolidated Statements of Cash Flows—for the years [removed: ended](#i39cdee5f0c374353affc19f158b4853c_115)] [added: ended](#id87c1e19981e404fb2b458e86ff35366_121)] December 31, [removed: 2023[,](#i39cdee5f0c374353affc19f158b4853c_115) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_115) 2021] [added: 2024[,](#id87c1e19981e404fb2b458e86ff35366_121) 2023[, and](#id87c1e19981e404fb2b458e86ff35366_121) 2022] | | | [removed: [77](#i39cdee5f0c374353affc19f158b4853c_115)] [added: [75](#id87c1e19981e404fb2b458e86ff35366_121)] | | |
| [Notes to the Consolidated Financial [removed: Statements](#i39cdee5f0c374353affc19f158b4853c_118)] [added: Statements](#id87c1e19981e404fb2b458e86ff35366_124)] | | | [removed: [78](#i39cdee5f0c374353affc19f158b4853c_118)] [added: [76](#id87c1e19981e404fb2b458e86ff35366_124)] | | |
We have audited the accompanying Consolidated Balance Sheets of Healthpeak Properties, Inc. and subsidiaries (the “Company”) as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] the related Consolidated Statements of Operations, Comprehensive Income (Loss), Equity and Redeemable Noncontrolling Interests, and Cash Flows, for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] and the related Notes and the schedules listed in the Index at Item 15 (collectively referred to as the “financial statements”).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2023] [added: 2024] and [removed: 2022,] [added: 2023,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2023,] [added: 2024,] in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 9, 2024,] [added: 4, 2025,] expressed an unqualified opinion on the Company’s internal control over financial reporting.
[removed: Critical] [added: *Critical] Audit [removed: Matter][added: Matter Description*]
The critical audit [removed: matter] [added: matters] communicated below [removed: is a matter] [added: are matters] arising from the current-period audit of the financial statements that [removed: was] [added: were] communicated or required to be communicated to the audit committee and that (1) [removed: relates] [added: relate] to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit [removed: matter] [added: matters] below, providing [removed: a] separate [removed: opinion] [added: opinions] on the critical audit [removed: matter] [added: matters] or on the accounts or disclosures to which [removed: it relates.][added: they relate.]
Impairments — Real Estate — Refer to Notes 2 and [removed: 5] [added: 6] to the financial statements
Given the Company’s evaluation of impairment indicators, forecasted cash [removed: flows] [added: flows,] and sales prices of a long-lived asset requires management to make significant estimates and assumptions related to market capitalization rates, market prices per unit, and/or forecasted cash flows, performing audit procedures required a high degree of auditor judgment and an increased extent of effort.
- We tested the effectiveness of controls over impairment of real estate assets, including those over identifying impairment [removed: indicators] [added: indicators,] and the determination of forecasted undiscounted cash flows and sales prices for real estate assets.
- We performed an independent search for impairment indicators through the evaluation of several factors including an analysis of industry and market [removed: data, a comparison of real estate asset implied capitalization rates to market capitalization rates,] [added: data] and trends in financial performance.
- For real estate assets where indicators of impairment were determined to be present, we subjected a sample of undiscounted cash flow models to testing by (1) evaluating the source information [added: and assumptions] used by management, (2) testing the mathematical accuracy of the undiscounted cash flow models, [added: and] (3) evaluating management’s intended hold [removed: period, and (4) performing an independent recoverability test based on market data.][added: period.]
| | | | [added: 2024 | | | | | |] 2023 | | | | | | 2022 | | |
| Buildings and improvements | | | $ | [removed: 13,329,464] [added: 16,115,283] | | | | | $ | [removed: 12,784,078] [added: 13,329,464] | |
| Development costs and construction in progress | | | [removed: 643,217] [added: 880,393] | | | | | | [removed: 760,355] [added: 643,217] | | |
| Land and improvements | | | [removed: 2,647,633] [added: 2,918,758] | | | | | | [removed: 2,667,188] [added: 2,647,633] | | |
| Accumulated depreciation and amortization | | | [removed: (3,591,951)] [added: (4,083,030)] | | | | | | [removed: (3,188,138)] [added: (3,591,951)] | | |
| Net real estate | | | [removed: 13,028,363] [added: 15,831,404] | | | | | | [removed: 13,023,483] [added: 13,028,363] | | |
| Loans receivable, net of reserves of [removed: $2,830] [added: $10,499] and [removed: $8,280] [added: $2,830] | | | [removed: 218,450] [added: 717,190] | | | | | | [removed: 374,832] [added: 218,450] | | |
| Investments in and advances to unconsolidated joint ventures | | | [removed: 782,853] [added: 936,814] | | | | | | [removed: 706,677] [added: 782,853] | | |
| Accounts receivable, net of allowance of [removed: $2,282] [added: $2,243] and [removed: $2,399] [added: $2,282] | | | [removed: 55,820] [added: 76,810] | | | | | | [removed: 53,436] [added: 55,820] | | |
| Cash and cash equivalents | | | [added: | | | $ | 119,818 | | | | | $ |] 117,635 | | | | | [added: $] | 72,032 | | | [added: | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 119,818 | | | | | $ | 117,635 | | | | | $ | 72,032 | |]
| Restricted cash | | | [added: | | | 64,487 | | | | | |] 51,388 | | | | | | 54,802 | | | [added: | | | — | | | | | | — | | | | | | — | | | | | | 64,487 | | | | | | 51,388 | | | | | | 54,802 | | |]
| Intangible assets, net | | | [removed: 314,156] [added: 817,254] | | | | | | [removed: 418,061] [added: 314,156] | | |
| Assets held for sale, net | | | [removed: 117,986] [added: 7,840] | | | | | | [removed: 49,866] [added: 117,986] | | |
| Right-of-use asset, net | | | [removed: 240,155] [added: 424,173] | | | | | | [removed: 237,318] [added: 240,155] | | |
| Other assets, net | | | [removed: 772,044] [added: 942,465] | | | | | | [removed: 780,722] [added: 772,044] | | |
| Total assets | | | $ | [removed: 15,698,850] [added: 19,938,255] | | | | | $ | [removed: 15,771,229] [added: 15,698,850] | |
| Bank line of credit and commercial paper | | | $ | [removed: 720,000] [added: 150,000] | | | | | $ | [removed: 995,606] [added: 720,000] | |
| Term loans | | | [removed: 496,824] [added: 1,646,043] | | | | | | [removed: 495,957] [added: 496,824] | | |
| Senior unsecured notes | | | [removed: 5,403,378] [added: 6,563,256] | | | | | | [removed: 4,659,451] [added: 5,403,378] | | |
| Mortgage debt | | | [removed: 256,097] [added: 356,750] | | | | | | [removed: 346,599] [added: 256,097] | | |
| Intangible liabilities, net | | | [removed: 127,380] [added: 191,884] | | | | | | [removed: 156,193] [added: 127,380] | | |
| Liabilities related to assets held for sale, net | | | [removed: 729] [added: —] | | | | | | [removed: 4,070] [added: 729] | | |
Critical Audit Matters
Business Combination – Physicians Realty Trust Merger Valuation — Refer to Notes 2 and 3 to the financial statements
The Company completed the acquisition of Physicians Realty Trust on March 1, 2024 for total consideration of $3.0 billion.
The Company accounted for this acquisition as a business combination.
Accordingly, the purchase price was allocated to the assets acquired, liabilities assumed, and noncontrolling interests based on their relative fair values, including approximately $3.7 billion of consolidated real estate, $891 million in related intangible assets, and $150 million in related intangible liabilities.
The fair value determination of the real estate assets acquired and liabilities assumed required management to make significant estimates related to assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates.
Given the fair value determination of assets acquired and liabilities assumed requires management to make significant estimates and assumptions such as market land values, discount rates, capitalization rates, costs to execute similar leases, and fair market lease rates, performing audit procedures to evaluate the reasonableness of these assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.
*How the Critical Audit Matter Was Addressed in the Audit*
Our audit procedures related to the fair value of real estate assets acquired and liabilities assumed included the following, among others:
- We tested the effectiveness of controls over the purchase price allocation, including management’s controls over the identification of real estate assets, and the valuation methodology for estimating the fair value of real estate assets acquired and liabilities assumed.
- With the assistance of our fair value specialists, we evaluated the reasonableness of the (1) valuation methodology, (2) relevant market data, and (3) assumptions used in the valuation of land, buildings, and related intangible assets and liabilities, including testing the mathematical accuracy of the calculations, and comparing management’s assumptions to independently validated data sources used by market participants.
- We assessed the accuracy and completeness of the underlying data used in the valuation of land, buildings, and related intangible assets and liabilities including in-place lease agreements, square footage, and historical operating data.
February 4, 2025
| Cash and cash equivalents | | | 119,818 | | | | | | 117,635 | | |
| Restricted cash | | | 64,487 | | | | | | 51,388 | | |
| December 31, 2023 | | | 547,156 | | | | | | $ | 547,156 | | | | | $ | 10,405,780 | | | | | $ | (4,621,861) | | | | | $ | 19,371 | | | | | $ | 6,350,446 | | | | | $ | 525,596 | | | | | $ | 6,876,042 | | | | | $ | 48,828 | |
| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 243,142 | | | | | | — | | | | | | 243,142 | | | | | | 24,111 | | | | | | 267,253 | | | | | | 50 | | |
| Shares issued as part of the Merger | | | 162,231 | | | | | | 162,231 | | | | | | 2,611,916 | | | | | | — | | | | | | — | | | | | | 2,774,147 | | | | | | — | | | | | | 2,774,147 | | | | | | — | | |
| Repurchase of common stock | | | (10,592) | | | | | | (10,592) | | | | | | (180,098) | | | | | | — | | | | | | — | | | | | | (190,690) | | | | | | — | | | | | | (190,690) | | | | | | — | | |
| Noncontrolling interests acquired as part of the Merger | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 133,684 | | | | | | 133,684 | | | | | | 3,109 | | |
| December 31, 2024 | | | 699,485 | | | | | | $ | 699,485 | | | | | $ | 12,847,252 | | | | | $ | (5,174,279) | | | | | $ | 28,818 | | | | | $ | 8,401,276 | | | | | $ | 653,738 | | | | | $ | 9,055,014 | | | | | $ | 2,610 | |
| Merger-related post-combination stock compensation expense | | | 16,223 | | | | | | — | | | | | | — | | | | | |
| Proceeds from the Callan Ridge JV transaction, net | | | 125,662 | | | | | | — | | | | | | — | | | | | |
| Cash paid in connection with the Merger, net | | | (179,215) | | | | | | — | | | | | | — | | | | | |
On March 1, 2024, the Company completed its planned merger with Physicians Realty Trust (see Note 3).
At December 31, 2024 and 2023, straight-line rent receivable, net of allowance, was $338 million and $310 million, respectively.
Straight-line rent receivable is included in other assets, net in the Consolidated Balance Sheets.
*Management Fee Income*
The Company provides various services to certain of its unconsolidated joint ventures in exchange for fees and reimbursement.
These services are considered related party transactions under ASC 850, *Related Party Disclosures*.
Management fee income is recognized in interest income and other on the Consolidated Statements of Operations.
Initial direct costs are included in other assets, net in the Consolidated Balance Sheets.
At December 31, 2024 and 2023, the balance of net initial direct costs were $204 million and $172 million, respectively.
Business Combinations
For the Company’s real estate acquisitions that are accounted for as business combinations, such as the Merger, the Company allocates the acquisition consideration (excluding acquisition costs) to the assets acquired, liabilities assumed, and noncontrolling interests at fair value as of the acquisition date.
Any excess of the consideration transferred relative to the fair value of the net assets acquired is accounted for as goodwill.
Acquisition costs related to business combinations are expensed as incurred.
The fair values are determined using standard valuation methodologies, such as the cost, market, and income approach.
These methodologies require various assumptions, including those of a market participant.
Other assets, net consist primarily of straight-line rent receivable (as discussed above), initial direct costs (as discussed above), deferred income taxes (see Note 17), goodwill (see Note 10), corporate assets (see Note 7), derivative assets (see Note 22), other equity investments (as discussed below and see Note 19), and prepaid expenses.
February 9, 2024
| Gain (loss) on debt extinguishments | | | — | | | | | | — | | | | | | (225,824) | | |
| Reclassification adjustment realized in net income (loss) | | | — | | | | | | — | | | | | | (251) | | |
| Total comprehensive (income) loss attributable to noncontrolling interests’ share in discontinued operations | | | — | | | | | | — | | | | | | (2,539) | | |
| December 31, 2020 | | | 538,405 | | | | | | $ | 538,405 | | | | | $ | 10,175,235 | | | | | $ | (3,976,232) | | | | | $ | (3,685) | | | | | $ | 6,733,723 | | | | | $ | 556,227 | | | | | $ | 7,289,950 | | | | | $ | 57,396 | |
| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 505,540 | | | | | | — | | | | | | 505,540 | | | | | | 20,346 | | | | | | 525,886 | | | | | | 44 | | |
| Exercise of stock options | | | 97 | | | | | | 97 | | | | | | 3,194 | | | | | | — | | | | | | — | | | | | | 3,291 | | | | | | — | | | | | | 3,291 | | | | | | — | | |
| December 31, 2022 | | | 546,642 | | | | | | $ | 546,642 | | | | | $ | 10,349,614 | | | | | $ | (4,269,689) | | | | | $ | 28,134 | | | | | $ | 6,654,701 | | | | | $ | 527,897 | | | | | $ | 7,182,598 | | | | | $ | 105,679 | |
| Loss (gain) on debt extinguishments | | | — | | | | | | — | | | | | | 225,824 | | | | | |
Healthpeak® acquires, develops, owns, leases, and manages healthcare real estate.
*UPREIT Reorganization*
Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be subsidiaries of Healthpeak OP.
The Merger Agreement contains customary representations, warranties, and covenants, as well as certain termination rights for the Company and Physicians Realty Trust, in each case, as more fully described in the Merger Agreement.
In addition, the Company has engaged service providers, including investment banks and advisors, to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters.
In connection with these services, the Company expects to be required to pay success-based fees to the extent that certain conditions, including the closing of the transactions contemplated by the Merger Agreement, are met.
As of December 31, 2023, the Company expects to incur approximately $22 million of such success fees.
As closing of the transactions contemplated by the Merger Agreement has not occurred, no such amounts have been paid or accrued through December 31, 2023.
In connection with the Mergers, the Company filed a Registration Statement on Form S-4 with the SEC on December 15, 2023 (the “Initial Filing”), as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with their respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.
Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of the Company’s stockholders and the shareholders of Physicians Realty Trust.
The parties expect the Mergers to close on March 1, 2024.
If the Mergers are not consummated by July 31, 2024 (unless extended under certain circumstances), either the Company or Physicians Realty Trust may terminate the Merger Agreement.
*Government Assistance.* In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, *Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance* (“ASU 2021-10”), which increased the transparency of government assistance including the disclosure of the types of assistance, an entity’s accounting for assistance, and the effect of the assistance on an entity’s financial statements.
*Reference Rate Reform.* From March 2020 to December 2022, the FASB issued a series of ASUs that provide optional expedients that may be elected through December 31, 2024 to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on financial reporting.
The amendments in these ASUs were effective immediately upon issuance.
During the first quarter of 2023, the Company amended certain of its variable rate mortgage debt and the related interest rate swap agreements to change the interest rate benchmark from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) and accordingly, the Company elected to apply certain practical expedients provided by these ASUs related to cash flow hedges.
These expedients and the effects of reference rate reform have not had a material impact on the Company’s consolidated financial position, results of operations, cash flows, or disclosures.
The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024.
In 2021, the Company closed the following lab acquisitions: (i) eight acquisitions in Cambridge, Massachusetts for $498 million, (ii) one acquisition in San Diego, California for $20 million, and (iii) 12 acres of land for $128 million in South San Francisco, California.
Also during 2021, the Company closed the following outpatient medical acquisitions: (i) one outpatient medical building in Nashville, Tennessee for $13 million, (ii) one outpatient medical building in Denver, Colorado for $38 million, (iii) a portfolio of 14 outpatient medical buildings for $371 million (the “Outpatient Medical Building Portfolio”), (iv) one outpatient medical building in Fort Lauderdale, Florida for $16 million, (v) one outpatient medical building in Wichita, Kansas for $50 million, (vi) three outpatient medical buildings in Morristown, New Jersey for $155 million, (vii) two outpatient medical buildings in Dallas, Texas for $60 million, (viii) one outpatient medical building in Seattle, Washington for $43 million, (ix) one outpatient medical building in New Orleans, Louisiana for $34 million, and (x) one outpatient medical building in Cambridge, Massachusetts for $55 million.
Also during the three months ended March 31, 2023, the Company sold two outpatient medical buildings for $32 million, resulting in total gain on sales of $21 million.
During the three months ended June 30, 2022, the Company sold three outpatient medical buildings and one outpatient medical land parcel for $27 million, resulting in total gain on sales of $10 million.
During the three months ended September 30, 2022, the Company sold two outpatient medical buildings for $9 million, resulting in total gain on sales of $1 million.
*Sunrise Senior Housing Portfolio*
In January 2021, the Company sold a portfolio of 32 SHOP assets (the “Sunrise Senior Housing Portfolio”) for $664 million, resulting in an immaterial loss on sale, which is recognized in income (loss) from discontinued operations, and provided the buyer with: (i) financing of $410 million and (ii) a commitment to finance up to $92 million of additional debt for capital expenditures (see Note 7).
Upon completion of the license transfer process in June 2021, the Company sold the two remaining Sunrise senior housing triple-net assets for $80 million, resulting in a gain on sale of $22 million, which is recognized in income (loss) from discontinued operations.
*Brookdale Triple-Net Portfolio*
In January 2021, the Company sold 24 senior housing assets in a triple-net lease with Brookdale for $510 million, resulting in total gain on sale of $169 million, which is recognized in income (loss) from discontinued operations.
*Additional SHOP Portfolio*
In January 2021, the Company sold a portfolio of 16 SHOP assets for $230 million, resulting in total gain on sale of $59 million, which is recognized in income (loss) from discontinued operations.
*HRA Triple-Net Portfolio*
An excerpt. Shown here: 40 of 1,082 rewritten, 40 of 761 added and 40 of 396 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2024 filing and the FY2023 filing.
Item 9A. Controls and Procedures
8 rewritten, 1 added, 1 removed, 22 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, [removed: 2023.][added: 2024.]
Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, [removed: 2023.][added: 2024.]
Based on our evaluation under the framework in *Internal Control—Integrated Framework (2013)*, our management concluded that our internal control over financial reporting was effective as of December 31, [removed: 2023.][added: 2024.]
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2023] [added: 2024] has been audited by Deloitte & Touche LLP, the independent registered public accounting firm that audited the financial statements included in this Annual Report on Form 10-K, as stated in their report, which is included herein.
*Changes in Internal Control Over Financial Reporting.* There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the [removed: fourth] quarter [removed: of 2023] [added: ended December 31, 2024] that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
We have audited the internal control over financial reporting of Healthpeak Properties, Inc. and subsidiaries (the “Company”) as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2023,] [added: 2024,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, [removed: 2023,] [added: 2024,] of the Company and our report dated February [removed: 9, 2024,] [added: 4, 2025,] expressed an unqualified opinion on those financial statements.
February 4, 2025
February 9, 2024
Item 9B. Other Information
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
During the three months ended December 31, [removed: 2023,] [added: 2024,] none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.
Item 10. Directors, Executive Officers and Corporate Governance
2 rewritten, 0 added, 0 removed, 3 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Except as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2023] [added: 2024] in connection with our [removed: 2024] [added: 2025] Annual Meeting of Stockholders.
Current copies of our Code of Business Conduct and Ethics and Vendor Code of Business Conduct and Ethics are posted on our website at [removed: www.healthpeak.com/esg/governance.][added: www.healthpeak.com/corporate-impact/governance.]
Item 11. Executive Compensation
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
The information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2023] [added: 2024] in connection with our [removed: 2024] [added: 2025] Annual Meeting of Stockholders.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
The information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2023] [added: 2024] in connection with our [removed: 2024] [added: 2025] Annual Meeting of Stockholders.
Item 13. Certain Relationships and Related Transactions, and Director Independence
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
The information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2023] [added: 2024] in connection with our [removed: 2024] [added: 2025] Annual Meeting of Stockholders.
Item 14. Principal Accountant Fees and Services
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
The information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2023] [added: 2024] in connection with our [removed: 2024] [added: 2025] Annual Meeting of Stockholders.
Item 15. Exhibits and Financial Statement Schedules
72 rewritten, 22 added, 0 removed, 27 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Consolidated Balance Sheets - December 31, [removed: 2023] [added: 2024] and [removed: 2022][added: 2023]
Consolidated Statements of Operations - for the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021][added: 2022]
Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021][added: 2022]
Consolidated Statements of Equity and Redeemable Noncontrolling Interests - for the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021][added: 2022]
Consolidated Statements of Cash Flows - for the years ended December 31, [added: 2024,] 2023, [removed: 2022,] and [removed: 2021][added: 2022]
| 2.1+ | | | | | | [Agreement and Plan of Merger, dated February 7, 2023, by and among Healthpeak Properties, Inc., New Healthpeak, Inc. and Healthpeak Merger Sub, [removed: Inc. (incorporated herein by reference to Exhibit 2.1 to Healthpeak’s filed).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex2-1.htm)] [added: Inc.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex2-1.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 2.2+ | | | | | | [Agreement and Plan of Merger, dated as of October 29, 2023, by and among Healthpeak Properties, Inc., DOC DR Holdco, LLC (formerly Alpine Sub, LLC), DOC DR, LLC (formerly Alpine OP Sub, LLC), Physicians Realty Trust and Physicians Realty [removed: L.P.](http://www.sec.gov/Archives/edgar/data/765880/000110465923112569/tm2329359d4_ex2-1.htm)] [added: L.P.](https://www.sec.gov/Archives/edgar/data/765880/000110465923112569/tm2329359d4_ex2-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | October 30, 2023 | | |
| 3.1 | | | | | | [Articles of Amendment and Restatement of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, [removed: 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-1.htm)] [added: 2023.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-1.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 3.2 | | | | | | [Articles of Amendment of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, [removed: 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-2.htm)] [added: 2023.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-2.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| [removed: 3.3] [added: 3.4] | | | | | | [Amended and Restated Bylaws of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.), dated February 10, [removed: 2023](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-4.htm)] [added: 2023.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-4.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 4.1 | | | | | | [Indenture, dated as of September 1, 1993, between Healthpeak and The Bank of New York, as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000101706202001055/dex42.txt)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000101706202001055/dex42.txt)] | | | | | | Registration Statement on Form S‑3/A (Registration No. 333-86654) | | | | | | May 21, 2002 | | |
| 4.1.1 | | | | | | [First Supplemental Indenture dated as of January 24, 2011, to the Indenture, dated as of September 1, 1993, by and between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465911002678/a11-3301_5ex4d1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465911002678/a11-3301_5ex4d1.htm)] | | | | | | Current Report on Form 8‑K | | | | | | January 24, 2011 | | |
| 4.1.2 | | | | | | [Second Supplemental Indenture, dated as of February 10, 2023, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-1.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 4.2 | | | | | | [Amended and Restated Indenture, dated as of February 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (amending and restating the Indenture, dated November 21, 2012, between Healthpeak and the [removed: trustee).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm)] [added: trustee).](https://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm)] | | | | | | Registration Statement on Form S-3ASR (Registration No. 333‑269718) | | | | | | February 13, 2023 | | |
| 4.2.1 | | | | | | [Fifth Supplemental Indenture, dated January 21, 2015, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465915003694/a15-2154_5ex4d1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465915003694/a15-2154_5ex4d1.htm)] | | | | | | Current Report on Form 8‑K | | | | | | January 21, 2015 | | |
| 4.2.2 | | | | | | [Sixth Supplemental Indenture, dated May 20, 2015, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465915039674/a15-9767_5ex4d1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465915039674/a15-9767_5ex4d1.htm)] | | | | | | Current Report on Form 8‑K | | | | | | May 20, 2015 | | |
| 4.2.3 | | | | | | [Eighth Supplemental Indenture dated July 5, 2019, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] | | | | | | Current Report on Form 8‑K | | | | | | July 5, 2019 | | |
| 4.2.4 | | | | | | [Ninth Supplemental Indenture dated November 19, 2019, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] | | | | | | Current Report on Form 8‑K | | | | | | November 21, 2019 | | |
| 4.2.5 | | | | | | [Tenth Supplemental Indenture, dated June 23, 2020, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | June 23, 2020 | | |
| 4.2.6 | | | | | | [Eleventh Supplemental Indenture, dated July 12, 2021, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | July 12, 2021 | | |
| 4.2.7 | | | | | | [Twelfth Supplemental Indenture, dated November 24, 2021, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | November 24, 2021 | | |
| 4.2.8 | | | | | | [Thirteenth Supplemental Indenture, dated January 17, 2023, between Healthpeak and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | January 17, 2023 | | |
| 4.2.9 | | | | | | [Fourteenth Supplemental Indenture, dated as of February 10, 2023, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-2.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-2.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 4.2.10 | | | | | | [Fifteenth Supplemental Indenture, dated as of May 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-1.htm)] [added: trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | May 10, 2023 | | |
| [removed: 4.3] [added: 4.4] | | | | | | [Form of 6.750% Senior Notes due [removed: 2041.](http://www.sec.gov/Archives/edgar/data/765880/000110465911002678/a11-3301_5ex4d5.htm)] [added: 2041.](https://www.sec.gov/Archives/edgar/data/765880/000110465911002678/a11-3301_5ex4d5.htm)] | | | | | | Current Report on Form 8-K | | | | | | January 24, 2011 | | |
| [removed: 4.4] [added: 4.5] | | | | | | [Form of 3.400% Senior Notes due [removed: 2025.](http://www.sec.gov/Archives/edgar/data/765880/000110465915003694/a15-2154_5ex4d1.htm)] [added: 2025.](https://www.sec.gov/Archives/edgar/data/765880/000110465915003694/a15-2154_5ex4d1.htm)] | | | | | | Current Report on Form 8-K | | | | | | January 21, 2015 | | |
| [removed: 4.5] [added: 4.6] | | | | | | [Form of 4.000% Senior Notes due [removed: 2025.](http://www.sec.gov/Archives/edgar/data/765880/000110465915039674/a15-9767_5ex4d1.htm)] [added: 2025.](https://www.sec.gov/Archives/edgar/data/765880/000110465915039674/a15-9767_5ex4d1.htm)] | | | | | | Current Report on Form 8-K | | | | | | May 20, 2015 | | |
| [removed: 4.6] [added: 4.7] | | | | | | [Form of 3.250% Senior Notes due [removed: 2026.](http://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] [added: 2026.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] | | | | | | Current Report on Form 8-K | | | | | | July 5, 2019 | | |
| [removed: 4.7] [added: 4.8] | | | | | | [Form of 3.500% Senior Notes due [removed: 2029.](http://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] [added: 2029.](https://www.sec.gov/Archives/edgar/data/765880/000110465919039426/a19-12489_1ex4d1.htm#Exhibit4_1_064900)] | | | | | | Current Report on Form 8-K | | | | | | July 5, 2019 | | |
| [removed: 4.8] [added: 4.9] | | | | | | [Form of 3.000% Senior Notes due [removed: 2030.](http://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] [added: 2030.](https://www.sec.gov/Archives/edgar/data/765880/000110465919066251/tm1923469d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | November 21, 2019 | | |
| [removed: 4.9] [added: 4.10] | | | | | | [Form of 2.875% Senior Notes due [removed: 2031.](http://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] [added: 2031.](https://www.sec.gov/Archives/edgar/data/765880/000110465920076057/tm2023139d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | June 23, 2020 | | |
| [removed: 4.10] [added: 4.11] | | | | | | [Form of 1.350% Senior Notes due [removed: 2027.](http://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] [added: 2027.](https://www.sec.gov/Archives/edgar/data/765880/000110465921091175/tm2120897d4_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | July 12, 2021 | | |
| [removed: 4.11] [added: 4.12] | | | | | | [Form of 2.125% Senior Notes due [removed: 2028.](http://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] [added: 2028.](https://www.sec.gov/Archives/edgar/data/765880/000110465921143581/tm2132635d5_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | November 24, 2021 | | |
| [removed: 4.12] [added: 4.13] | | | | | | [Form of 5.250% Senior Notes due [removed: 2032.](http://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] [added: 2032.](https://www.sec.gov/Archives/edgar/data/765880/000110465923004247/tm233500d1_ex4-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | January 17, 2023 | | |
| [removed: 4.13] [added: 4.14] | | | | | | [Form of 5.250% Senior Notes due 2032, including the form of Notation of [removed: Guarantee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-2.htm)] [added: Guarantee.](https://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-2.htm)] | | | | | | Current Report on Form 8-K | | | | | | May 10, 2023 | | |
| [removed: 4.14†] [added: 4.15†] | | | | | | [Description of Healthpeak Capital [removed: Stock.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex41412312023.htm)] [added: Stock.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex41512312024.htm)] | | | | | | | | | | | | | | |
| 10.1 | | | | | | [Operating Agreement of Healthpeak OP, LLC, dated as of February 10, [removed: 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-1.htm)] [added: 2023.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-1.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 10.2 | | | | | | [Omnibus Assignment, Assumption and Amendment, dated February 7, 2023 by and between Healthpeak OP, LLC (formerly Healthpeak Properties, Inc.) and Healthpeak Properties, Inc. (formerly New Healthpeak, [removed: Inc.).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-4.htm)] [added: Inc.).](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-4.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 10.3 | | | | | | [removed: [Second] [added: [Third] Amended and Restated Credit Agreement, dated as of [removed: September 20, 2021,] [added: December 9, 2024,] by and among [removed: Healthpeak,] [added: Healthpeak OP,] as borrower, [added: Healthpeak, DOC Holdco and DOC DR, as guarantors,] the lenders referred to therein, and Bank of America, N.A., as administrative [removed: agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465921117350/tm2127869d1_ex10-1.htm)] [added: agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924126775/tm2430417d1_ex10-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | [removed: September 20, 2021] [added: December 9, 2024] | | |
| [removed: 10.3.1] [added: 10.5.1] | | | | | | [Consent and Amendment No. 1 to [removed: Second Amended and Restated Credit] [added: Term Loan] Agreement, dated as of February 10, 2023, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., the lenders listed therein and Bank of America, N.A., as administrative [removed: agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-2.htm)] [added: agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-3.htm)] | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |
| 3.3 | | | | | | [Articles of Amendment of Healthpeak Propert](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm)[i](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm)[es, Inc., effective February 29, 2024.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-1.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 3.5 | | | | | | [Amendment to the Bylaws of Healthpeak Properties, Inc., effective March 1, 2024.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex3-2.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 4.1.3 | | | | | | [T](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[hird Supplemental Indenture, dated as of March 1, 2024, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm) [guarantor](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[, DOC DR Holdco, LLC, as guarantor, DOR DR, LLC, as guarantor, and the Bank of New York Mellon Trust Company](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm)[, N.A., as trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-6.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 4.2.11 | | | | | | [Sixteenth Supplemental Indenture, dated as of March 1, 2024, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, DOC DR Holdco, LLC, as guarantor, DOC DR, LLC, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-7.htm) | | | | | | Current Form on Form 8-K | | | | | | March 1, 2024 | | |
| 4.3 | | | | | | [Senior Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee.](https://www.sec.gov/Archives/edgar/data/765880/000110465924012371/tm245193d2_ex4-8.htm) | | | | | | Registration Statement on Form S-3 ASR (File No. 333-276954) | | | | | | February 8, 2024 | | |
| 4.3.1 | | | | | | [First Supplemental Indenture, dated as of March 7, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 4.300% Senior Notes due 2027.](https://www.sec.gov/Archives/edgar/data/765880/000110465924012371/tm245193d2_ex4-9.htm) | | | | | | Registration Statement on Form S-3 ASR (File No. 333-276954) | | | | | | February 8, 2024 | | |
| 4.3.2 | | | | | | [Second Supplemental Indenture, dated as of December 1, 2017, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 3.950% Senior Notes due 2028.](https://www.sec.gov/Archives/edgar/data/765880/000110465924012371/tm245193d2_ex4-10.htm) | | | | | | Registration Statement on Form S-3 ASR (File No. 333-276954) | | | | | | February 8, 2024 | | |
| 4.3.3 | | | | | | [Third Supplemental Indenture, dated as of October 13, 2021, among Physicians Realty L.P., Physicians Realty Trust and U.S. Bank National Association, as trustee, including the form of the 2.625% Senior Notes due 2031.](https://www.sec.gov/Archives/edgar/data/765880/000110465924012371/tm245193d2_ex4-11.htm) | | | | | | Registration Statement on Form S-3 ASR (File No. 333-276954) | | | | | | February 8, 2024 | | |
| 4.3.4 | | | | | | [Fourth Supplemental Indenture, dated as of March 1, 2024, among DOC DR, LLC, as issuer, DOC DR Holdco, LLC, as guarantor, Healthpeak Properties, Inc., as guarantor, Healthpeak OP, LLC, as guarantor, and U.S. Bank Trust Company, National Association, as trustee, including the form of guarantee.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex4-5.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 10.4 | | | | | | [Third Amended and Restated Credit Agreement, dated as of September 24, 2021, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex10-2.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 10.4.1 | | | | | | [First Amendment to the Third Amended and Restated Credit Agreement, dated as of March 31, 2023, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex10-3.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 10.4.2 | | | | | | [Second Amendment to Third Amendment to Third Amended and Restated Credit Agreement, dated as of May 24, 2023, among Physicians Realty L.P., as borrower, Physicians Realty Trust, as guarantor, the lenders party thereto and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex10-4.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 10.4.3 | | | | | | [Consent and Third Amendment to Third Amended and Restated Credit Agreement, dated as of February 21, 2024, by and among DOC DR, LLC, DOC DR Holdco, LLC, Healthpeak Properties, Inc., Healthpeak OP, LLC, the lenders party thereto, and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924029661/tm247564d1_ex10-1.htm) | | | | | | Current Report on Form 8-K | | | | | | March 1, 2024 | | |
| 10.4.4 | | | | | | [Fourth Amendment to Third Amended and Restated Credit Agreement, dated as of December 9, 2024, by and among DOC DR, as borrower, Healthpeak, Healthpeak OP and DOC Holdco, as guarantors, the lenders referred to therein, and KeyBank National Association, as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924126775/tm2430417d1_ex10-3.htm) | | | | | | Current Report on Form 8-K | | | | | | December 9, 2024 | | |
| 10.5.3 | | | | | | [Amendment No. 3 to Term Loan Agreement, dated as of December 9, 2024, by and among Healthpeak OP, as borrower, Healthpeak, DOC Holdco and DOC DR, as guarantors, the lenders referred to therein, and Bank of America, N.A., as administrative agent.](https://www.sec.gov/Archives/edgar/data/765880/000110465924126775/tm2430417d1_ex10-2.htm) | | | | | | Current Report on Form 8-K | | | | | | December 9, 2024 | | |
| 10.6.1 | | | | | | [Amendment No. 1 to At-the-Market Equity Offering Sales Agreement, dated March 11, 2024, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward Purchasers.](https://www.sec.gov/Archives/edgar/data/765880/000110465924032999/tm248304d1_ex1-1.htm) | | | | | | Current Report on Form 8-K | | | | | | March 11, 2024 | | |
| 10.6.2 | | | | | | [Amendment No. 2 to At-the-Market Equity Offering Sales Agreement, dated May 3, 2024, among Healthpeak Properties, Inc., Healthpeak OP, LLC, the Sales Agents, the Forward Sellers and the Forward Purchasers](https://www.sec.gov/Archives/edgar/data/765880/000162828024033154/ex10106302024.htm)[.](https://www.sec.gov/Archives/edgar/data/765880/000162828024033154/ex10106302024.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | July 26, 2024 | | |
| 10.12.4* | | | | | | [Form of 2023 Performance Incentive Plan Retentive LTIP Unit Agreement (adopted in 2024).](https://www.sec.gov/Archives/edgar/data/765880/000162828024018706/ex101003312024.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 26, 2024 | | |
| 10.12.6* | | | | | | [Form of 2023 Performance Incentive Plan 3-Year Performance-Based LTIP Unit Agreement (adopted in 2024).](https://www.sec.gov/Archives/edgar/data/765880/000162828024018706/ex101203312024.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 26, 2024 | | |
| 10.12.7*† | | | | | | [Form of 2023 Performance Incentive Plan Non-NEO OP Unit Award Agreement (adopted 2025, for converted awards).](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex1012712312024.htm) | | | | | | | | | | | | | | |
| 10.15 | | | | | | [Offer Letter, dated February 29, 2024, from Healthpeak Properties, LLC to John T. Thomas.](https://www.sec.gov/Archives/edgar/data/765880/000162828024018706/ex10803312024.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 26, 2024 | | |
| 19.1† | | | | | | [Insider Trading Policy.](https://www.sec.gov/Archives/edgar/data/765880/000162828025003748/ex19112312024.htm) | | | | | | | | | | | | | | |
An excerpt. Shown here: 40 of 72 rewritten, all 22 added and all 0 removed. The counts are complete. For every sentence, read Item 15. Exhibits and Financial Statement Schedules in the FY2024 filing and the FY2023 filing.
Item 16. Form 10-K Summary
10 rewritten, 10 added, 4 removed, 15 unchanged
Read the full itemFY2024 item · filed February 4, 2025FY2023 item · filed February 9, 2024
Dated: February [removed: 9, 2024][added: 4, 2025]
| /s/ SCOTT M. BRINKER | | | | | | President and Chief Executive Officer, Director | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ PETER A. SCOTT | | | | | | Chief Financial Officer | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ SHAWN G. JOHNSTON | | | | | | Executive Vice President and Chief Accounting Officer | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ KATHERINE M. SANDSTROM | | | | | | Chair of the Board | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ BRIAN G. CARTWRIGHT | | | | | | Director | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ JAMES B. CONNOR | | | | | | Director | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ R. KENT GRIFFIN, JR. | | | | | | Director | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| /s/ SARA [removed: GROOTWASSINK] [added: G.] LEWIS | | | | | | Director | | | | | | February [removed: 9, 2024] [added: 4, 2025] | | |
| Sara [removed: Grootwassink] [added: G.] Lewis | | | | | | | | | | | | | | |
| /s/ JOHN T. THOMAS | | | | | | Vice Chair of the Board | | | | | | February 4, 2025 | | |
| John T. Thomas | | | | | | | | | | | | | | |
| /s/ PAMELA J. KESSLER | | | | | | Director | | | | | | February 4, 2025 | | |
| Pamela J. Kessler | | | | | | | | | | | | | | |
| /s/ AVA E. LIAS-BOOKER | | | | | | Director | | | | | | February 4, 2025 | | |
| Ava E. Lias-Booker | | | | | | | | | | | | | | |
| /s/ TOMMY G. THOMPSON | | | | | | Director | | | | | | February 4, 2025 | | |
| Tommy G. Thompson | | | | | | | | | | | | | | |
| /s/ RICHARD A. WEISS | | | | | | Director | | | | | | February 4, 2025 | | |
| Richard A. Weiss | | | | | | | | | | | | | | |
| /s/ CHRISTINE N. GARVEY | | | | | | Director | | | | | | February 9, 2024 | | |
| Christine N. Garvey | | | | | | | | | | | | | | |
| /s/ DAVID B. HENRY | | | | | | Director | | | | | | February 9, 2024 | | |
| David B. Henry | | | | | | | | | | | | | | |